Form PTO-1594 (Rev. 06/04)	
OMB Collection 0651-0027 (exp.	6/30/2005)

U.S. DEPARTMENT OF COMMERCE United States Patent and Trademark Office

RECORDATION FOR TRADEMAR	
To the Director of the U. S. Patent and Trademark Office: Pleas	e record the attached documents or the new address(es) below.
1. Name of conveying party(ies)/Execution Date(s): Lynx Therapeurics, Inc. Individual(s)	2. Name and address of receiving party(ies): Additional names, addresses, or citizenship attached? No Name: Silicon Valley Bank dba Silicon Valley East Internal Address: Street Address: 3003 Tasman Drive City: Santa Clara State: CA Country: US Association Citizenship: General Partnership Citizenship:
3. Nature of conveyance: Assignment Merger Security Agreement Change of Name Other 4. Application number(s) or registration number(s) and A. Trademark Application No.(s): 75/631946 76/162496	LimitedPartnership Citizenship: Corporation Citizenship: Other: Chartered Bank Citizenship: CA If assignee is not domiciled in the United States, a domestic representative designation is attached: (Designations must be a separate document from easignment) I identification or description of the Trademark(s): B. Trademark Registration No.(s): 2607815 2756427 2650334 2503036 2505260 2646805 2640604 2661846 2661848 2586627 2856295
5. Name and address of party to whom correspondence concerning document should be mailed: Name: Christopher E. Kondrackí Address: 2001 Jefferson Davis Highway Suite 1007 Arlington, Virginia 22202	Additional sheet(s) attached? Yes No 6. Total number of applications and registrations involved: 7. Total Fee (37 CFR 2.6(b)(6) & 3.41): \$ 340.00 Authorized to be charged by credit card Authorized to be charged by Deposit Account Fees Enclosed
Phone Number: (703) 415-1555 Fax Number: (703) 415-1557 Email Address:	8. Payment Information: Deposit Account Number: 19-3545 Authorized User Name: Christopher E. Kondracki
9. Signature: Signature Signature Christopher E. Kondracki Name of Person, Signing	Total number of pages including cover sheet, ettachments, and documenta: 32

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "IP Agreement") is made as of the 28th day of December, 2004 by and between LYNX THERAPEUTICS, INC., a Delaware corporation with its principal place of business at 25861 Industrial Boulevard, Hayward, California 94545 ("Grantor"), and SILICON VALLEY BANK, a California-chartered bank, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at One Newton Executive Park, Suite 200, 2221 Washington Street, Newton, Massachusetts 02462, doing business under the name "Silicon Valley East" ("Lender").

RECITALS

- A. Lender has agreed to make advances of money and to extend certain financial accommodations to Grantor (the "Loan"), pursuant to a certain Loan and Security Agreement dated as of December 28, 2004 between Grantor and Lender, as amended from time to time (as amended, the "Loan Agreement"). The Loan is secured pursuant to the terms of the Loan Agreement. Lender is willing to enter into certain financial accommodations with Grantor, but only upon the condition, among others, that Grantor shall grant to Lender a security interest in certain Copyrights, Trademarks, Patents, and Mask Works, and other assets, to secure the obligations of Grantor under the Loan Agreement. Defined terms used but not defined herein shall have the same meanings as in the Loan Agreement.
- B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Lender a security interest in all of Grantor's right title and interest, whether presently existing or hereafter acquired in, to and under all of the Collateral (as defined therein).
- NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged and intending to be legally bound, as collateral security for the prompt and complete payment when due of Grantor's Indebtedness (as defined below), Grantor hereby represents, warrants, covenants and agrees as follows:
- 1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future indebtedness, obligations and liabilities to Lender (hereinafter, the "Indebtedness"), including, without limitation, under the Loan Agreement, Grantor hereby grants a security interest in all of Grantor's right, title and interest in, to and under its registered and unregistered intellectual property collateral (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:
 - (a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished, registered or unregistered, and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on **EXHIBIT A** attached hereto (collectively, the "Copyrights");
 - (b) Any and all trade secret rights, including any rights to unpatented inventions, know-how, operating manuals, license rights and agreements, and confidential information, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;
 - (c) Any and all design rights which may be available to Grantor now or hereafter existing, created, acquired or held;
 - (d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on **EXHIBIT B** attached hereto (collectively, the "Patents");

NO.390

- Any trademark and service mark rights, slogans, trade dress, and tradenames, trade styles, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on EXHIBIT C attached hereto (collectively, the "Trademarks");
- All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on EXHIBIT D attached hereto (collectively, the "Mask Works");
- Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;
- All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights, including, without limitation those set forth on EXHIBIT E attached hereto (collectively, the "Licenses");
- All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and
- All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.
- Authorization and Request. Grantor authorizes and requests that the Register of Copyrights and he Commissioner of Patents and Trademarks record this IP Agreement, and any amendments thereto, or copies hereof.
 - 3. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:
 - Except as set forth in the Perfection Certificate, Grantor is now the sole owner of the Intellectual Property Collateral, except for non-exclusive licenses granted by Grantor to its customers in the ordinary course of business:
 - Performance of this IP Agreement does not conflict with or result in a breach of any material agreement to which Grantor is bound;
 - During the term of this IP Agreement, Grantor will not transfer or otherwise encumber any interest in the Intellectual Property Collateral, except for non-exclusive licenses granted by Grantor in the ordinary course of business or as set forth in this IP Agreement;
 - To its knowledge, each of the Patents is valid and enforceable, and no part of the Intellectual Property Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Intellectual Property Collateral violates the rights of any third party;
 - Grantor shall promptly advise Lender of any material adverse change in the composition of the Colleteral, including but not limited to any subsequent ownership right of the Grantor in or to any Trademark, Patent, Copyright, or Mask Work specified in this IP Agreement;
 - Grantor shall (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents, Copyrights, and Mask Works, (ii) use its best efforts to detect infringements of the Trademarks, Patents, Copyrights, and Mask Works and promptly advise Lender in writing of material infringements detected and (iii) not allow any Trademarks, Patents, Copyrights, or Mask Works to be abandoned, forfeited or dedicated to the public without the written consent of Lender, which shall not be

unreasonably withheld, unless Grantor determines that reasonable business practices suggest that abandonment is appropriate;

- (g) Grantor shall take such further actions as Lender may reasonably request from time to time to perfect or continue the perfection of Lender's interest in the Intellectual Property Collateral;
- (h) This IP Agreement creates, and in the case of after acquired Intellectual Property Collateral this IP Agreement will create, at the time Grantor first has rights in such after acquired Intellectual Property Collateral, in favor of Lender a valid and perfected first priority security interest and collateral assignment in the Intellectual Property Collateral in the United States securing the payment and performance of the obligations evidenced by the Loan Agreement;
- (i) To its knowledge, except for, and upon, the filing of UCC financing statements, or other notice filings or notations in appropriate filing offices, if necessary to perfect the security interests created hereunder, no authorization, approval or other action by, and no notice to or filing with, any U.S. governmental authority or U.S. regulatory body is required either (a) for the grant by Grantor of the security interest granted hereby, or for the execution, delivery or performance of this IP Agreement by Grantor in the U.S. or (b) for the perfection in the United States or the exercise by Lender of its rights and remedies thereunder.
- (j) All information heretofore, herein or hereafter supplied to Lender by or on behalf of Grantor with respect to the Intellectual Property Collateral is accurate and complete in all material respects;
- (k) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Lender's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interest in any property included within the definition of the Intellectual Property Collateral acquired under such contracts; and
- (1) Upon any executive officer of Grantor obtaining actual knowledge thereof, Grantor will promptly notify Lender in writing of any event that materially adversely affects the value of any material Intellectual Property Collateral, the ability of Grantor to dispose of any material Intellectual Property Collateral or the rights and remedies of Lender in relation thereto, including the levy of any legal process against any of the Intellectual Property Collateral.
- 4. <u>Lender's Rights</u>. Lender shall have the right, but not the obligation, to take, at Grantor's sole expense, any actions that Grantor is required under this IP Agreement to take but which Grantor fails to take, after fifteen (15) days' notice to Grantor. Grantor shall reimburse and indemnify Lender for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this section 4.
- 5. <u>Inspection Rights.</u> Grantor hereby grants to Lender and its employees, representatives and agents the right to visit, during reasonable hours upon prior reasonable written notice to Grantor, any of Grantor's plants and facilities that manufacture, install or store products (or that have done so during the prior six-month period) that are sold utilizing any of the Intellectual Property Collateral, and to inspect the products and quality control records relating thereto upon reasonable written notice to Grantor and as often as may be reasonably requested, but not more than once in every six (6) months; provided, however, nothing herein shall entitle Lender access to Grantor's trade secrets and other proprietary information.

6. Further Assurances: Attorney in Fact.

(a) On a continuing basis, Grantor will, upon request by Lender, subject to any prior licenses, encumbrances and restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate

financing and continuation statements and collateral agreements and filings with the United States Patent and Trademarks Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as requested by Lender, to perfect Lender's security interest in all Copyrights, Patents, Trademarks, and Mask Works and otherwise to carry out the intent and purposes of this IP Agreement, or for assuring and confirming to Lender the grant or perfection of a security interest in all Intellectual Property Collateral.

- (b) In addition to section 6(a) above, Grantor shall not register any Copyrights or Mask Works in the United States Copyright Office unless it: (i) has given at least fifteen (15) days' prior written notice to Lender of its intent to register such Copyrights or Mask Works and has provided Lender with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits thereto); (ii) executes a security agreement or such other documents as Lender may reasonably request in order to maintain the perfection and priority of Lender's security interest in the Copyrights proposed to be registered with the United States Copyright Office; and (iii) records such security documents with the United States Copyright Office contemporaneously with filing the Copyright application(s) with the United States Copyright Office. Grantor shall promptly provide to Lender a copy of the Copyright application(s) filed with the United States Copyright Office, together with evidence of the recording of the security documents necessary for Lender to maintain the perfection and priority of its security interest in such Copyrights or Mask Works. Grantor shall provide written notice to Lender of any application filed by Grantor in the United States Patent Trademark Office for a patent or to register a trademark or service mark within 30 days of any such filing.
- (c) Grantor hereby irrevocably appoints Lender as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, Lender or otherwise, from time to time in Lender's discretion, upon Grantor's failure or inability to do so, to take any action and to execute any instrument which Lender may deem necessary or advisable to accomplish the purposes of this IP Agreement, including:
 - (i) To modify, in its sole discretion, this IP Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibit A, Exhibit B, Exhibit C, and Exhibit D hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents, Trademarks or Mask Works acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents, Trademarks, or Mask Works in which Grantor no longer has or claims any right, title or interest; and
 - (ii) To file, in its sole discretion, one or more financing or continuation statements and amendments thereto, or other notice filings or notations in appropriate filing offices, relative to any of the Intellectual Property Collateral, without notice to Grantor, with all appropriate jurisdictions, as Lender deems appropriate, in order to further perfect or protect Lender's interest in the Intellectual Property Collateral.
- 7. <u>Events of Default.</u> The occurrence of any of the following shall constitute an Event of Default under this IP Agreement:
 - (a) An Event of Default occurs under the Loan Agreement; or
 - (b) Grantor breaches any warranty or agreement made by Grantor in this IP Agreement,
- Remedies. Upon the occurrence and continuance of an Event of Default, Lender shall have the right to exercise all the remedies of a secured party under the California Uniform Commercial Code, including without limitation the right to require Grantor to assemble the Intellectual Property Collateral and any tangible property in which Lender has a security interest and to make it available to Lender at a place designated by Lender. Lender shall have a nonexclusive, royalty free license to use the Copyrights, Patents, Trademarks, and Mask Works to the extent reasonably necessary to permit Lender to exercise its rights and remedies upon the occurrence of an Event of Default. Grantor will pay any expenses (including reasonable attorney's fees) incurred by Lender in connection with the exercise of any of Lender's rights hereunder, including without limitation any expense incurred

in disposing of the Intellectual Property Collateral. All of Lender's rights and remedies with respect to the Intellectual Property Collateral shall be cumulative.

- 9. <u>Indemnity</u>. Grantor agrees to defend, indemnify and hold harmless Lender and its officers, employees, and agents against: (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this IP Agreement, and (b) all losses or expenses in any way suffered, incurred, or paid by Lender as a result of or in any way arising out of, following or consequential to transactions between Lender and Grantor, whether under this IP Agreement or otherwise (including without limitation, reasonable attorneys fees and reasonable expenses), except for losses arising from or out of Lender's gross negligence or willful misconduct.
- 10. <u>Termination</u>. At such time as Grantor shall completely satisfy all of the obligations secured hereunder, Lender shall execute and deliver to Grantor all releases, terminations, and other instruments as may be necessary or proper to release the security interest hereunder.
- 11. <u>Course of Dealing</u>. No course of dealing, nor any failure to exercise, nor any delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof.
- 12. <u>Amendments</u>. This IP Agreement may be amended only by a written instrument signed by both parties hereto.
- 13. <u>Counterparts</u>. This IP Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.
- 14. Law and Jurisdiction. This IP Agreement shall be governed by and construed in accordance with the laws of the State of California. GRANTOR ACCEPTS FOR ITSELF AND IN CONNECTION WITH ITS PROPERTIES, UNCONDITIONALLY, THE NON-EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE OF CALIFORNIA, AND GRANTOR ACCEPTS JURISDICTION OF THE COURTS AND VENUE IN SANTA CLARA COUNTY, CALIFORNIA, IN ANY ACTION, SUIT, OR PROCEEDING OF ANY KIND, AGAINST IT WHICH ARISES OUT OF OR BY REASON OF THIS AGREEMENT. NOTWITHSTANDING THE FOREGOING, THE LENDER SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST THE GRANTOR OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH THE LENDER DEEMS NECESSARY OR APPROPRIATE IN ORDER TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE THE LENDER'S RIGHTS AGAINST THE GRANTOR OR ITS PROPERTY.

GRANTOR AND LENDER EACH HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS. EACH PARTY RECOGNIZES AND AGREES THAT THE FOREGOING WAIVER CONSTITUTES A MATERIAL INDUCEMENT FOR IT TO ENTER INTO THIS AGREEMENT. EACH PARTY REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

15. <u>Confidentiality</u>. In handling any confidential information, Lender shall exercise the same degree of care that it exercises for its own proprietary information, but disclosure of information may be made: (i) to Lender's subsidiaries or affiliates in connection with their present or prospective business relations with Grantor; (ii) to prospective transferees or purchasers of any interest in the Loans; (iii) as required by law, regulation, subpoena, or other order, (iv) as required in connection with Lender's examination or audit; and (v) as Lender considers appropriate in exercising remedies under this Agreement. Confidential information does not include information that either: (a) is in the public domain or in Lender's possession when disclosed to Lender, or becomes part of the

lic domain after disclosure to Lender; or (b) is disclosed to Lender by a third party, if Lender reasonably does not w that the third party is prohibited from disclosing the information.

[Remainder of page intentionally left blank]

EXECUTED under the laws of the State of California on the day and year first written above.

Address of Grantor:	GRANTOR:
25861 Industrial Boulevard	LYNX THERAPEUTICS, INC.
Jayward, California 94545	By: Many L. Schrauh
	Name: MARY L. SCHRAMKE
	Title: ACTING CHIEF EXECUTIVE OFFICE
	SILICON VALLEY BANK
	Ву:
	Name:
	Title:

EXECUTED under the laws of the State of California on the day and year first written above.

Address of Grantor:	GRANTOR:
25861 Industrial Boulevard	LYNX THERAPEUTICS, INC.
Hayward, California 94545	Ву:
	Name:
	Title;
	SILICON VALLEY BANK
•	By: Mary Stall
	Name: Michael J Hanguich
	Title 52 Win Prails + Life Same

Exhibit "A" attached to that certain Intellectual Property Security Agreement dated <u>Dembler 28</u>, 2004.

EXHIBIT "A"

COPYRIGHTS

SCHEDULE A - ISSUED COPYRIGHTS

COPYRIGHT DESCRIPTION REGISTRATION NUMBER

DATE OF ISSUANCE

None.

SCHEDULE B - PENDING COPYRIGHT APPLICATIONS

FIRST DATE

COPYRIGHT **DESCRIPTION** APPLICATION NUMBER

DATE OF FILING

DATE OF CREATION

OF PUBLIC DISTRIBUTION

None,

SCHEDULE C - UNREGISTERED COPYRIGHTS (Where No Copyright Application is Pending)

DATE AND RECORDATION NUMBER OF IP AGREEMENT WITH OWNER OR ORIGINAL

GRANTOR IF

ORIGINAL AUTHOR

OF COPYRIGHT

AUTHOR OR OWNER OR OWNER OF COPYRIGHT IS

FIRST DATE

IS DIFFERENT

DIFFERENT FROM

COPYRIGHT DATE OF DESCRIPTION CREATION

OF DISTRIBUTION

FROM GRANTOR

GRANTOR

None.

500477 v2/HN @q6502!.DOC -8-

EXHIBIT "B"

PATENTS

PATENT

DESCRIPTION DOCKET NO. COUNTRY SERIAL NO. FILING DATE STATUS

See Attached.

500477 v2/HN @q6502!.DOC -9-

							Who is a line of		· · · · · · · · · · · · · · · · · · ·
don DNA in a Host						Section Section 5			arbeidste
	1004	동	10/606,400	ROMOS	R/20M3 Pending	10/806 too	e ordered		
and Compostions for Ordering Restriction				9	4	- Constant	000000		
Fragments	1002-02 2D	S	10/706,118	11/12/03 Pending	Pendino	10/706 119	11/12/03		
Method of Nucleic Add Amplification	1005-C		10/449010	6/2/03	6/2/03 Pending	10/449010	Pulcus Polizi ii i		
Methods of Nucleic Acid Amplification and					c c		2000		
Sequencing	1006	55	09/806531	10/10/01	Pending	09/806531	10/10/01		
Isothermal Amplification of Nucleic Acids on a Solid					•				
Support	1007	S	10/433,965	11/3/03	11/3/03 Pending	10/433.965	11/3/03		
Methods for Detecting Genomewide Sequence							3		
Variations Associated with a Phenotype	1000	เร	10/378688	3/4/03	3/4/03 Pending	10/378688	3/4/03		
Stacked Microfluidic Device	1009	SU	10/138889	5/2/02	5/2/02 Pending	10/138889	5/2/02		
Molecular Tagging System	802-02 JP DIV	Þ	2003-350142	ļ	Filed	2003-350142			
Method of Nucleic Acid Amplication	1005	US.	09/402,277	9/30/99	Pending	09/402,277	9/30/99		
Electrophoresis Apparatus and Method	818 WOAU	AU	40929/99	5/21/99	5/21/99 Granted	40929/99	5/21/99 758515	758515	7/3/03
Method for Making Complementary Oligonucleotide									
Tag Sels	817 AU	ΑU	1603100	11/1/90	11/1/99 Granted	1603100	11/1/99 766502	766502	1/29/04
Molecular Tagging System	802-02 AU-2D	ΑU	52663/99	10/4/99 Filed	Filed	52663/99	10/4/99		
Polymorphic DNA Fragments and Uses Thereof	826-02 AU	A U	32378/00	2/2/00	Filed	32378/00	2/2/00		
DNA Sequencing by Stepwise Ligation and									
Сівауаде	801-05 WOAU	AU	23791/95	3/24/95	Granted	23791/95	3/24/95 685628	685628	5/7/98
Solid Phase Synthesis of Oligonucleolide N3'->P5'		•							
Phosphoram	035-01 WOAU	AU	6178/96	6/14/96	6/14/96 Granted	6178/96	6/14/96 703509	703509	
Oligonucleotide N3'->P5' Phosphoramidates:									
Hybridization and	005-01 AU	ð	21900/95	3/20/95	Granted	21900/95	3/20/95 704549	704549	
Molecular Tagging System	802-02 WOAU	ΑU	42778/96	10/12/95	10/12/95 Granted	42778/96	10/12/95 712929	712929	3/2/00
Oligorudeolide Tags for Sorting and Identification	802-05 WOAU	AU	61020/96	96/9/9	6/6/96 Granted	61020/96	96/9/9	6/6/96 0718357	7/27/00
DNA Sequencing by Parallel Oligonucleotide		•							
Extensions .	805 AU	≥	55490/96	4/16/96	Granted	55490/96	4/16/96 718937	718937	8/17/00
Sequencing by Ligation of Encoded Adaptors	808-1 WOAU	۲	3374097	6/2/97	6/2/97 Granted	3374097	6/2/97	6/2/97 733762	9/6/01
System and Apparatus for Sequential Processing							-		
of Analyles	B15 WOAU	2	77155/98	5/22/98	Granted	77155/98	5/22/98 736321	736321	7/26/01
Improvements in Adaptor-Based Sequence									
Analysis	814 WOAU	Ą	71213/98	4/14/98	4/14/98 Granted	71213/98	4/14/98 737331	737331	9/16/01
Melhad of mapping restriction sites in									
polynucleotides	816-01 WOAU	ΑU	81709/98	6/25/98	6/25/98 Granted	81709/98	6/25/98 739863	739963	2/7/02

7/3/03 1/29/04 5/7/98 5/7/98 9/2/00 9/6/01 1/16/01 2/7/02

Solid Phase Selection of Offerentially Expressed]	= - -		 -	
Genes DNA Sequencing by Parallel Olinomidentics	822-02 AU	AU	21139/99	1/8/99/Gran	Granted	21139/99	1/8/99 754929	54929	
Extensions	805-01 AU DIV	<u></u>	JR74300	AMeino			•		
DNA Sequencing by Stepwise Ligation and		ā	1000	-17 OBIO	Hand Glauff	48/1300	4/16/96/754991	54991	3420403
Cleavage	801-05 AS	ቅ	95916916	SOFFERE	Conlad	05045045	5		
DNA Sequencing by Stepwise Ligation and			000	00/470	Dailip Ko Mazara	91801658	3/24/95 E	3/24/95/EP00703991	5/16/01
Cleavage	801-05 BE	BELG	95916916	3/54/95	3/24/95 Granted	05016016		707000	
Electrophoresis Apparatus and Method	B18 WOCA	Q	2232775	5/91/99 Filed	Flori	9939775	CONTROL	374/90 EPU/U3981	STORUT
Method of Mapping Restriction Sites in		!		0.000	2	0172033	GELIZIE		
Palynucleotides	816-01 WOCA	Ş	2295325	675/08 Filed	<u> </u>	9905395	3		
Oligonucleotide N3'->P6' Phosphoramidates;					100	P-00000	ORICZIO		
Hybridization and	005-01 CA	ξ	2184375	320095 Filed	<u> </u>	9194975	30000		
DNA Sequencing by Stepwise Ligation and						r	CEMPAR		
Cleavage	801-05 CA	CA	2163662	3/24/95 Filed	Filed	2163662	3/24/95		
Oligonucleotide Tags for Sorting and Identification	802-05 CA	CA	2222581	ADIAN ADIAN	6/6/96 Granted	3333564	5		
DNA Sequencing by Parallel Oligonucleotide				9	C) ci iii	- 00	19C777 06/040	190777	9/11/04
Extensions	805 CA	£	2218017	4/16/96	4/16/96 Granted	9918017	America	740047	3
Massively Parallel Signature Sequencing by					0.000	r	1100127 Sept.	210017	12/2/03
Ligation of Encoded Adaptors	808-1 WOCA	S	2256700	6/2/97 Filed	<u>Fi</u>	2256700	6/2/Q7		
Data Analysis and Display System for Ligation-				 			3		
Based DNA Sequ	833-01 CA	£	2366738	2/15/01 Filed	Fled	2388738	2/15/01	_	
Improvements in Adaptor-Based Sequence							!		
Analysis	B14 WOCA	ÇA	2286400	4/14/98 Filed	Filed	2286400	4/14/98		
Polymorphic DNA Fragments and Uses Thereof	826-02 CA	CA	2372131	2/18/00 Filed	Filed	2372131	2/18/00		
Oligonudeotide Tags for Sorling and Identification	802-05 CA DIV	Ş	2332731	6/6/96 Filed	Fied	2332731			
Molecular Tagging System	802-02 CA	Ş	2202167	10/12/95	10/12/95 Granted	2202167	10/19/05/99/0167	202467	10/H6/ng
Solid Phase Synthesis of Oligonucleotide N3'->P5'							5	i i	2
Prospection Complementary Oliconsolation Method for Making Complementary Oliconsolation (Application)	035-01 WUCA	Ş	2245666	6/14/96 Filed	Filed	2245666	6/14/96		
Tag Sets	817 WOCA	Ď	2349836	11/1/00 5164	n D	32A0926	1		
System and Apparalus for Sequential Processing				7.7.	9	- 60	1000		
of Analytes	915 WOCA	S A	2291180	5/22/98 Filed		2291190	7.735/GB		
Solid Phase Selection of Differentially Expressed						- 00	20077		
Genes	822 WOCA	CA	2317695	1/8/99 Filed	Filed	2317695	1/8/99		
Oligonucleotide Tags for Sorting and Identification	802-05 CN	£.	96196135.X	6/6/96 Gran	Granted	0040040E V	5	Biolog octoors v	5

Page

Measure Lateral Signature Sequencing by		_						
Ligation of Encoded Adaptors	808-1 WOCN	Z Z	97197101 3	2007 1007 1007	<u>.</u>			
Solid Phase Selection of Differentially Expressed		9	0.101.01	Dell-1, rerzio	8	97197101.3	6/2/97	
Genes	822 WOCZ	CZ	PV2000-3545	150000		<u>,</u>		
Molecular Tagging System	802-02 WOCZ	3	PV 966-07	104305		PV2000-2545	1/8/99	
Sequencing by Ligation of Encoded Adaptors	909-1 WOO2	3 6	7 4 000 A 7	UI CR/Z L/D I		PV 866-97	10/12/95	
Olionardenido Tana for Cartina and Line III			96B786-A-2	6/2/9/ In	Inactive	PV-397998	6/2/97	
Solid Phase Synthesis of Oligonucleolide N3:->P5'	27.00-700	2	PV3926-97	6/6/96 Inactive	active	PV3926-97	6/6/96	
Phosphoram	035-01 WOCZ	ु र	P\/2620_08	84499	[3		
Oligonucleotide N3'->P5' Phosphoramidates:		İ	00-070	DBILL (0.6.75.1 20		86-679ZA-d	8/14/96	
Hybridization and	005-01 CZ	3	P\/>745.06	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	Ī	i i		
DNA Sequencing by Stepwise Ligation and				1 Colors	186	QR-Ch/ZAH	3/20/95	
Cleavage	801-05 DN		95916916	o sovece		On) 	
Electrophoresis Apparatus and Method	1918 WOEP	<u>.</u>	0.007.000	Delivers Carazio	allen	95916816	3/24/95 EP0703991	991 5/16/01
		1	0.07447000	Burgua ABN 240	Butons	98924423.9	5/21/99	
High Resolution Physical Maps of Genomic DNA	816-01 WOEP	건	98931639.3	ADS/GR Dending	Podina	000245		
Synthesis of BranchesNucleic Acids	003 WOEP	전	94923335.7	7/5/04 61	Parents of	04000000	6/25/98	
Oligonucleolide N3'->P5' Phosphoramidates:				200	Patrioncie	// CCPCZ6heballoniani	7/5/94	
Hybridization and	005-01 EP	ng C	95914800 B	'a solucie		0000		
Solid Phase Synthesis of Oligonucleatide N3'->P5'				Superior of the state of the st	S. C. C.	9,000 1400	3/20/95	
Phosphoram	035-01 WOEP	EPC	96919449.7	6/14/96 Granted	anted	96919449.7	6/14/96	
Oligonucleolide Tags for Sorting and Identification	802-05 EP	m O	96918333.4	6/6/96 Pending		08048232		
DNA Sequencing by Parallel Oligonucleotide				9	0 0 0	00010000.4	orayao	
Extensions	805 EP	mPC	96912800.8	4/16/96 Pandian	3	06045800 a		
Measurement of Gene Expression Profiles in				5	2	0.00021000	98/01/#	
Toxicity Determin	813 EP	문	96940238.7	10/11/96 AI	handona	10/11/96 Abandona 060/0739 7		
Massively Parallel Sequencing of Sorted					0010	1.003010001	08/11/01	
Polynucleolides	803-01 EP	Po	99105019.6	3/19/99 Pending		00105010 6	1	
Data Analysis and Display System for Ligation-	ļ			9	S. Co.	201000100	31,120	
Based DNA Sequ	833-01 EP	m C	1910827.3	2/15/01 Pending		1910827 3		
Improvements in Adaptor-Based Sequence				1	9	01004150	10,617	
Analysis	814 WOEP	B 공	98918252.2	4/14/98 Pendino		98918252 2	### #IDO	
Massively Parallel Signature Sequencing by	•				4	000 10E0E.F	06/1-1/4	
Ligation of Encoded Adaptors	808-1 WOEP	EPC	97929757.9	6/2/97 Pendir	ending	97929757.9	6/2/97	
Polymorphic DNA Fragments and Uses Thereof	826-02	m C	910255,9	2/2/00 Pending	Society.	010355. 0		•
Methods for Sorting Polynucleolides Using				1,000	. 3	0.0000	00/2/2	 -
Olignuclealide Tag .	802-02 EP	mPC	95941325.3	10/13/05 Danding	<u>}</u>	050443))	

Capanage Clearly Having Digallosic and		_	-]			
Therapeutic App	004 EP	공	94921471 2	7/1/04	Ahandana	nunna sia n		}
Method for Making Complementary Oligonucleotide			0.000	+671.69	// //a-f/Abalidone	7.1741Z648 Janu	7/1/94	
Tag Sets	817 WOEP	EPC C	99959733	4414400	1			
System and Apparatus for Sequential Processing		į	00000	IDUBA BEN 111	Gulbua	88958733	11/1/99	
of Analytes	815 WOEP	eg C	98925137 A	RDVC4.v) } }	2000	! : :	
Solid Phase Selection of Differentially Expressed		,	000000000000000000000000000000000000000	M(13.1 D0(77.10	Biolia	9.75157608	5/22/98	
Genes	822 WOEP	m P C	99901448.3	1/9/00	1/9/00 Dending	000011125		
DNA Sequencing by Stepwise Ligation and				100	Gianio	0.0441088	BB/B/L	
Cleavage	801-05 EP	ë R	95916916	30405	3/24/05 Granted	05010010	3	_
Massively Parallel Sequencing of Sorted					000	400 0010	3/24/90 EPU/03991	5/16/01
Polynucleotides	803 EP	т О	95937322 f	10/19/05/Granlad	Granled	050070000		
Simultaneous Sequencing of Tagged				1	Con those	0.72010000	10/12/95 EP0/86014	
Polynucleotides	807 EP		96942790 5	11/10/04 Crantal	0	000107000		
Oligonucleotide N3'->P5' Phosphoramidates:				10,00	Ci di lia	G.08 (74epg.	13/19/96/EP0040803	5/2/03
Hybridization and	005-01 FI	T)	963581	3/20/05/Eiled		Dhanoi	5	
Molecular Tagging System	802-02 WOFN	Ę.	971473	10/12/05 Filed		10000	CENTZIC	-
DNA Sequencing by Stepwise Ligation and				107 14700	1 100	014110	C677.01	
Cleavage	801-05 FR	₽	95916916	3/24/95	3/2d/95 Granted	05018046	1	1 :
Massively Parallel Sequencing of Sorted				 		00010010	166507043 C6/67/2	5/16/01
Polynucleotides	803 FR	#	95937322.6	10/12/95 Granled	Gran er	05037725 6	104380	
DNA Sequencing by Stepwise Ligation and Cheavage	Source Co	3					107 12 00 14 07 000 14	12) 13/89
mRNA Molecules for Use as Indicators for the		ć	00010010	CAMPZ	Dellipio Calabre	01.691.606	3/24/95 EP0703991	5/16/01
Activation and	501 DE	GER.	10021834.2	5/8/00 Filed	7	C VEBICULI	n de la colonia	
Massively Parallel Sequencing of Sorted				1		10001007.0	STOP OF	
Polynucleotides	803 DE	R	95937322.6	10/12/95 Granted	Granted	95937322 A	4040305 70504 A	
DNA Sequencing by Stepwise Ligation and						1000	# Opg 1 Cerz 1 m (66/C1/71
Cleavage	801-05 DE	DE	69520917.5-0	3/24/95	3/24/95 Granted	695209 tz.5-na	3/24/05/E007/13004	74004
System and Apparatus for Sequential Processing							areaso El orosal	9 90
of Analytes	815 WOEPHK	¥	105481.5	9/1/00 Filed		105481 5	0/1300	
Massively Parallel Signature Sequencing by					.		9 200	
Ligation of Encoded Adaptors	808-1 HK	<u> </u>	99105687.9	12/4/99 Filed	<u>E</u>	99105687,9	12/4/99	
Okonucleolide Taos for Syrling and Identification	SUS TK	<u> </u>	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7		1			
Solid Phase Selection of Differentially Expressed		-	00100241.1	090 3 GB 101	Filed	7.17700168	86917	
Genes	822 WOHU	픋	P0100242	1/9/99 inactiv	Dactive e	Potonovo	A Joseph	•
Molecular Tagging System	802-02 HU	Ξ	P9801187	10/12/95 Filed	ŀ	P9801187	40/4 2/02 20/4 2/04	
Sequencing by Ligation of Encoded Adaptors	808-1 WOHU	골	P0003944	6/2/97 Fled		PMMTGAA	15 May 2	
			1, 100	95701	300	L PARCOLL I	672/9/	

15/99 15/99

		_	-			-		
Oligorucleotide Tags for Sorting and Identification Solid Phase Synthesis of Oligonucleotide N3:>P5'	802-05 HU	E	P9900910	6/6/96 Filed	Fled	P9900910	96/9/9	
	035-01 WOHII	<u> </u>	DODOGEOG		.		w Grade	
tide N3'->P5' Phosphoramidales;		Ī	L9807070	6/14/98 Filed	E ez	P9902526	6/14/96	
	005-01 HU	Ξ	ONECORDO	3				
DNA Sequencing by Stepwise Ligation and		ā	1 00000	SZW95 FN60	Page	P9602549	3/20/95	
uencing by Stepwise Ligation and	001-00-10	T T	95916916	3/24/95 Grant	Granted	95916916	3/24/95 EP0703991	57.662
	801-05 IT	Ä A	95916916	3/24/95	Granked	олод b од		
Electrophoresis Apparatus and Method	818 WOJP	-	3000 551340	F 134 500		ora roalo	3/24/95 EP0703991	5/16/01
DAIA	946 04 460 5	; ²	842100003	86/17/e	Flied	2000-551249	5/21/99	
	180 14 1900	;	97/605-11	6/25/98 Filed	Filed	11-505776	6/25/98	
olide N3'->P5'	900	5	7-503683	7/5/94	7/5/94 Inaclive	7-503683	7/5/94	
	035-01 WOJP	Ü	9-530107	SHAMS SHAMS				
eging System	802-02 WOJP	= - - 	9513309	40/40/00	1 2	1010c-6	6/14/96	
ei Oligonucleolide		9	CO CE	Della Cerzi Ari		8513298	10/12/95	
	4F 508	Þ	8531848	4/16/96 Filed		Rn21940	Harris	
	808-1 WOJP	-	10-500755	6/2/97 Filed	<u> </u>	10.500755	5 5 5 5	
Measulement of Gene Expression Profiles in	5	j					900	
Adaptor-Based Sequence	ora recor	F	08/515,240	10/11/96	Fled	09/515,240	10/11/96	
Analysis	814 WOJP	₽	10544260	4/14/98 Filed	필요	10544260	4/14/98	_
DNA Extension and Analysis with Rolling Primers	811-01 JP	চ	10-237840	8/24/98 Filed	Filed	10-237840	8/24/98	
Polymorphic DNA Fragments and Uses Thereof	826-02 JA	5	2000-601195	2/2/00 Filed	Filed .	2000-601195	2/2/00	<u></u>
Oligonucleotide Tags for Sorting and Identification	802-05 JP	₹	9-501818	8888 <u>1</u>	<u>n</u>	7 7 7 8		
	801-05 Jp	5	7505706	3 9		0000	0,0,99	
13'->P5' Phosphoramidates:		-	0.00	OF TAILOR	192	7070703	3/24/95	
_	005-01 JP	늉	7-524793	320/95		7,594702	35000	
Method for Making Complementary Oligonucleotide				S	i c	7724790	CRMZ/C	
	917 WOJP	등	2000-579783	11/1/99 Filed	<u>21</u> 2 .	2000-579793	44400	
Apparatus for Sequential Processing				1		1000	BRITIL	
Solid Phase Selection of Differentials Transport	ALOW GLB	\ \	10-550767	5/22/98 Filed	Filed	10-550757	5/22/98	
	90 MO 16	<u> </u>				,		
	022 11001	2	2000-527674	1/8/99 Filed	Filed	2000-527674	1/8/99	

		9004	8/3/01 Abandone 01/24271	handone	8/3/01	01/24271	PCT	OM BZB	Lieurophionage Apparatus and Methon
		11/19/96	96/18708	nactive	11/19/96 nactive	BO 10 708	2	200 110	Electrophoresis Apparatus and Moderal
				•		0070700	- PG	807 WO	Polynucleotides
		4/16/96	96/05245	madive	eviloreni lorani re	0470000	5		Simultaneous Sequencing of Tagmed
				6	444600	08/040/45	PCT	805 WO	Extensions
		96/9/9	96/09513	Mactive	overed mach	0108010	2		DNA Sequencing by Parallel Olinonurleovide
					2012	08/00643	TOT	802-05 WO	Oligonucleotide Tags for Sorting and Identification
		3/24/95	95/03678	nactive	3/24/95 Inactive	95/03678	PCT	901-09 WO	Cicaralie
			-				ļ !		Cleanage Cleanage
		6/14/96	96/10418	Inadive	6/14/96 Inactive	96/10418	PCI	035-01 WO	Phosphoram
		CEMIZIC		0					Solid Phase Synthesis of Oligonucleolide N3'->P5'
		50000	05/03575	nadiva	3/20/95 Inadive	95/03575	PCT	005-01 WO	Hybridization and
		46,1077	- 100,000	mode	, ,				Oligonudeotide N3'->P5' Phosphoramidates:
		08/07/0	04/07557	7/5/9d Inactive	75.54	94/07557	PCT	003 WO	Synthesis of Branches Nucleic Acids
•		and a	98/13335	nactive	6/25/98 Inactive	98/13335	PCT	816-01 WO	High Resolution Physical Maps of Genomic DNA
		1/8/99	99/00666	1/8/99 Inactive	1/8/99	99/00/566	PCT	822 WO	Calco
		91							Some Flase serection of Differentially Expressed
		5/21/00	PCT/US99/1127	nactive	5/21/99 Inactive	PCT/US99/11	PCT	818 WO	Cold Discovering Apparatus and Melhod
		המומנים	00/04349	2/2/00 Inactive	2/2/00	00/04349	PCT	826-02 WO	Polymorphic DNA Fragments and Uses Thereof
<u> </u>		3/20/95	P963891	Filed	3/20/95 Filed	P963891	NO.	005-01 NO	Hybridization and
		ce/zrwe	1971044	1 100	, ,				Oligonucleotide N3'->P5' Phosphoramidates:
	797/82	ZB/55/ /8/2/0	0074644	T	10/12/05	P971644	NO	802-02 WONO	Muecular ragging System
	700700	Policia Control	Piggsaga	Fied	6/2/97	P19985698	NO O	808-1 WONO	Sequencing by Ligation of Encoded Adaptors
		#J6/06	P975744	Filed	96/0/96	P975744	8	802-05 NO	Oligonucleotide Tags for Sorting and Identification
		1/8/99	20003531	Filed	1/8/99 Filed	20003531	Š	822 WONO	Genes
5/16/01	3/24/95 EP0703991	3/24/95	9189166	Ģranne0	OLATAN PLANT	00000			Solid Phase Selection of Differentially Expressed
					13 A 10 A	95916916		801-05 NL	Cleavage
516601	3/24/95 EP0703991	3/24/95	95916916	3/24/95 Granted	3/24/95	95916916	LUXE	OUI-US-LX	DNA Sequencing by Stepwise Ligation and
		GENTZIE	8070010	100	<u> </u>		i i	904 051 V	PNA Sequencing by Stepwise Ligation and Cleavage
) 	70 m		3/20/05 Filed	96-705131	泵	005-01 KR	Hybridization and
		10/12/95	97-702433	Inactive.	Deul Ce/Zuni	DO4201-16			Oligonucleotide N3'->P5' Phosphoramidales:
		6/6/96	97-709024	6/6/96 Inactive	96/9/9	97-709024	\$ 3	802-02 WOKR	Molecular Tagging System
5/20/04	1/8/99 433782	1/8/99	CRG2/00/-0002	Ofallier	O(a)		5	BN AR KONS	Oligonudeolide Tags for Sorting and Identification
			2007 7007	0	1 /9/00	2000-700758	分	822 WOKR	CERT
			- 					,	Carry Congression of Differentially Explessed

Page

						Ē		THE PROPERTY OF THE PROPERTY O
	1/8/99	Unknown	1 1 1 1	Della Gazon	T. C. Indiana	2 ;		Sequencing by Ligation of Engaded Adaptive
				4 2000	l Inknown	<u> </u>	622 WOPL	Genes
	2/15/01	25050110	pathoen.	S			,	Solid Phase Selection of Differentially Expressed
	,		nodi:	2/15/01 modi	01/05032	<u>P</u>	833-01 WO	Based DNA Sequ
	4/12/01	PC1/US01/1198	RIACHYB	torus Lorzyst	000000			Data Analysis and Display System for Ligation-
_	_		7 1 1 1	4140004	PCT///SO1/44	PCT	845-03 WO	Fragments
	6671.630	OCTOO!		400				Method and Compositions for Ordering Restriction
	Darzin	done 9920047		8/31/99 Ahar	99/20047	PCT	819 WO	Method of Screening for Genelic Polymorphism
	# Toolog	98/11224	Inactive	5/22/98 Inact	98/11224	PCT	815 WO	of Analytes
	68/1/11	0000	0.000					System and Apparatus for Sequential Processing
		99/25690	Inactive	11/1/99 Inact	99/25680	PCT	817 WO	ag Sets
	67/84	410101	Othorne					Method for Making Complementary Oligonucleolida
	1	0//075/4	200	7/1/94	94/07541	PCI	004 WO	Therapeutic App
,	111194	ZOJOHBOOTO I	2100040					Oligonucleolide Clamps Having Diagnostic and
•			ng tive	7/11/94	PCT/US94/07	PCT	001-/00 WO	Compounds Having Dia
	BR/FL/6	P 1721 Application	, mainagin	2.4				Auto-Ligating Oligonucleotide Antisense
	C6/71.M1	08/40073	Ahandono	9/14/98 Ahan	98/19273	PCT	038-01 WO	Polynucieotide Punication Method
	CRIZIAN	05/17704	10/12/95 Inardive	10/12/95	95/12791	PCT	802-02 WO	Microsoft Lagging System
	÷ 013	95/1267R	10/12/95 Inactive	10/12/95	95/12678	PCT	803 WO	Polynucieolides
-	06/07/6		.]į					Massivery Parallel Sequencing of Sorted
•	5	idone GANA384	2	9/26/96	96/15384	PCT	806 WO	Amplexagen
	18/2/9	77460110	24100041					Polynicaeolide Detection by Isothermal
	• •	17 m 470		6/2/97 Input	97/09472	PCT	808-1 WO	Ligation of Encoded Adaptors
	68.97.16	04,54000						Wasswely Parallel Signature Sequencing by
	2000000	99/22/85	nactive	9/28/99 Inac	99/22585	PCT	810-U1 WO	Prophetical of Organidateoride rags
	4/14/0R	98/07592	Inactive	4/14/98 Inad	98/07592	 <u>-</u>	019 610	Zymalic Synthesis of Oliconyologida Tana
] }	24.100	Analysis
	9/27/01	ndone 01/30396	Abandone	9/27/01 Abau	U1/30396	2	0000	Improvements in Adaptor-Rased Semigrop
			Ī			3	R33_04W/O	Nucleic Acid Se
	12/30/02	ndone(02/41381	Abandone	12/30/02 Abai	02/41381	PCT	OM 208	Method for Determining Relative Abundance of
	70/01/7							entification of Copies Copies
	12000	ndone 02/36950	Abandone	12/10/02 Aba	02/36950	PCT	906 WO	Expression
	12/10/02	nuone(02/39591		PDW Zouns (Z)	000			Method for the Analysis of Differential Gene
		-		19/10/00	02/39591	PCT	903 WO	Genelic Analysis of Gene Expression in Heterosis
	5/29/02	ndone 02/16792	Abandone	5/29/02/Aba	02/16/92	2	90	
	8/21/01	ndone 01/26115	Abandone	dv21/01 Aba	C1107/30	3	Orn EVB	Sequencing By Proxy
	10/11/96	our 1004Z			0438445	PCT	826-03WO	Polymorphic DNA Fragments and Uses Thereof
		ORI ROLL	10/11/96 Inaclive	1911.5	96/16342	PCI	813 WO	County Detailies
		-			_			

		7/17/01	U9/908, 130	L	granification	44,000,100			
					74404	00/009 130	<u></u>	815-01	of Analytes
		7/14/99	00/193/703	_	DARPORT HOOTE FEE				System and Apparatus for Sequential Processing
		<u> </u>	2014 10 701		7/14/00	60/143.705	SOS	820P	
				Tell an					Nucleic Acid Analysis by Sequence
		LOREZIO	, 004,000	۱,			S	839	
	-	FOOD	00/967 201	5	5/29/01 Pendi	09/867,201	SU	843	
•				To be filed			US	844	
			- 17					•	Past Organ Host Organ
-				Δ			US:	030	Description Constraint Contract Library
	 -	971/00	09/654;187	9/1/00 Pending	9/1/00	781, 509/60	5 6	930	ection
						200	ō	933-03	
		9/27/00	60/235,940	BARDRIII	001778	0400,040	10		Data Analysis and Display System for Liligation-
			1		0/27/00	60/235 940	<u></u>	832P	Noise Ratios
	<u></u>	10/8/99	60/158,483	10/8/99 Inactive	10/8/99	60/158,483	US	826-01	Method and Compositions for Enhancing Shorakha-
		2/22/99	60/121;023	2/22/99 Inactive	2/22/99	60/121,023	5	8200	Dolarosable DMA Francisco de Usas (1988)
60/62/13	8710770 00410	4,04							Polymorphic DNA Fractionals and Hope Thomas
	16700470	AMAIOO	09/549,748	4/14/00 Granted	4/14/00	09/549,748	S	1002-02	ragments
-		6/6/97	04070100		9.00		 -		Method and Compositions for Ordering Restriction
	_		98407040	6/6/97 Inactive	6/6/97	86107846	TAIW	WT 1-808	Ligation of Encodded Adaptors
5/16/01	3/24/95 EP0703991	3/24/96	95916916	3/24/95 Granted	3/24/95	90910010			Massively Parallel Signature Sequencing by
			-	_) ;	05010	- LIMS	801-05 CH	Cleavage
5/16/01	3/24/95 EP0703991	3/24/98	95916916	3/24/95 Inactive	3/24/95	95916916	CHARO	00 00	DNA Sequencing by Stepwise Ligation and
70,077							25.60	801-05 SE	Cleavage
7	1/8/99 74272	1/8/96	200003472-8	1/8/99 Granted	1/8/99	200003472-8	S.G.	DPO44 720	DNA Sequencing by Stepwise Ligation and
	00047	of E. c.				1	3	ROSO MACOSO	Genes
5/25/99	27903120/CB	Lorces Jemes	0-0 85088		6/2/97	9805810-0	SG	OOG-1 WUSG	Solid Phase Selection of Differentially Expressed
		200	9706203-8	6/6/96 Granted	6/6/96	9706203-6	SG	802-05 SG	Sequencing by Ligation of Engaged Adaptors
5/25/99	10/12/95 39092	10/12/9	9-0761018	- 1					Oligonucleolida Tage for Sorting and Idealing J.
5/18	3/24/95/23650	3/24/9	07049000	Granded 1	10/12/95	9701328-8	SG	802-02 SG	- Sang Ojerelli
-		,	Q501052 7	Granled	3/24/95	9501952-7	SING	801-05 SG	Molecular Tanging System
•	<u>on</u>	3/20/95	P316434	Filed	3/ZU/95 Filed				UNA Sequencing by Stepwise Ligation and
	0	08/11/20	· na.				모	005-01 PL	Hybridization and
	5	b	P328639	Fled	6/14/96 Filed	P328639	P	035-01 WOPL	Oligonudeolide N3'->P5' Phosphoramidatas:
·	<u>.</u>	6/6/96	P324000	6/6/96 Inactive	96/9/9	P324000	₽	802-05 WOPL	Solid Phase Synthesis of Oligonucleotide N3'->P5'
	-		- ,	-			-		Ollognucleofide Tans for Souther and Identify at the

		10/13/04	08/322,348	7	10/13/94 Inactive	08/322,348	US.	802-01	Holecular Lagging System
					_		S	835	
									Melhod and Compositions for Arraying Microbeads
 -	4	40/4/4		To be filed			SU	836	
		A 250	COE:CCC/BO	naclive	4/4/94 inactive	00/222,300	S	801-01 (SLC1)	Cleavage
11/25/03	4/30/01/6653077	4/30/0	6C7'001/En	- 1	10,000	00,100,100	-		DNA Sequencing by Stepwise Ligation and
-		Deven	00/706/06/		4/30/01 Cranted	09/786 254	SUS	819-01 US	Melhod of Screening for Genetic Polymorphism
	<u> </u>		00/005/222		1,9991	09/005,222	ક્ર	822	Genes
-		6/6/95	06/4/8/721	AATDRIN CRAM	Ceron	0011011	9		Solid Phase Selection of Differentially Expressed
•	<u> </u>	1	001440	no di co	arcios -	08/47A 794	<u></u>	0012-01	Compounds Having Dia
	**	3/18/94	C0C'017/00	BAMPEL	01.00	1000			Antisense
			00/040/00	5	3/18/04 insolin	08/210 505	S	006-00	
_	<u></u>	7/17/01	09/908,131	Pending	7/17/01 Pending	09/908,131	SS	815-02	Olimodeownihoendeolide NV DE
		ORIGIE	1.004						System and Apparatus for Sequential Processing
	. <u> </u>	01200	09/711 384	9/3/96 naclive	9,396	08/711,364	S	005-04	Hybridization and
		161770	09004,100						Oligonucleotide N3'->P5' Phosphoramidates:
			091994 490	lnactive .	1797C/B	08/884.189	US	816-00	ž
	<u>,a</u>	11/2/98	60/106,662	nactive	11/2/98 Inactive	60/106,662	Su	817P	Tag Sets
	US	7/11/95	0000,024	T PACTORS	24 1 000 mgc1 60	4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6			Method for Making Complementary Oligonucleotide
					7/11/05	08/500 524	ક્ર	9213 DIV D	Internucleoside Linka
	w W	7/2/93	08/087,386	112193 ITTACTIVE	112193	000,000	18		Novel Oligonucleotides Having Modified
				•	3	09/007 396	<u></u>	903	Connected Macromol
	3	6/7/96	08/659,924	nactive	ovinao luactive	470,000			Convergent Synthesis of Branched Multiply
-			-		2	08/850 004	<u>.</u>	9213 DIV E	Internucleoside Linka -
	7	6/30/97	08/885,827	naclive	6/30/97 Inaclive	779,090,00	5	10000	Novel Oligonucleolides Having Modified
+							<u></u>	9213 DIV D PWC	Internucleoside Linka
	<u> </u>	6/6/95	08/465,961	6/6/95 inactive	6,6792	108'COMON	Š		Novel Oligonucleolides Having Modified
					3	norace nor	ភ	9213 DIV A	internucleoside Linka
	<u>.~</u>	10/10/97	08/948,507	macove	e introver inactive	TOUCHO MO			Novel Oligonucleotides Having Modified
_			<u>-</u>	,	404060	4U3 BYDYBU	<u></u>	9213 FWC	internucieoside Linka
	<u> </u>	2/1/93	08/012/050	Inactive	2/1/93 Inactive	060,210,00	5		Novel Oligonucleolides Having Modified
1				•			<u></u>	9213	Internucleoside Linka
41/23/03	7/17/01 6654505	7/17/0	09/907,795	Granted	7/17/01 Granted	09/907,795	8	0.000	Novel Oligonucleotides Having Modified
7/24/01	8/6/98 6265163	67978	00,040		1 9		5	R15_03	of Analytes
	<u></u>	•	201300010		RIGINAL A	09/130,546	S	822-01	Grand
			_						

olide Tags for Sorting Polynucleotides elide Tags for Sorting and Identification feels Apparetus and Method feels Apparetus and Uses Thereof of Solid-Phase Arrays of itides by Chemic ending by Random Primer Extension feence Analysis By Stringency Class encing by Random Primer Extension for Candidate Genes for the osais Su or of Genes Controlling Complex Traits parties of Genes Controlling Complex Traits parties of Cholesterol Treatment and orgener for Cell Surface Polypeptides Affected orgener Synthesis of Oligonucleotide Tags Synthesis of Oligonucleot				2 2 2			Ų,	834	Decoder person
### District Sorting Polynicideoides 902-04 RE US 69/36/244 27/500 [Inadive 60/36/244 60/3	-			inactive			US:	000	so paga paparationa
Didde Tags for Sorting Projuntalization B02-04 RE US G9366.034 271500 Inactive G92192_464 271500 Inactive G9219_464_464 271500 Inactive G9219_464_464_464_464_464_464_464_464_464_46				nactive			5	026	hear populations
Decided Tags for Sorting Polynucleoides 1902 APRE US 004566,2814 221500 Inactive 004782,464 221500 Inactive 004782,643 221500 Inactive 004782,616 121500 Inactive 004782,616 121500 Inactive 004782,616 121500 Inactive 004782,617 121601 Inactive 004782,618 121601 Inactive 004782,619 121601 Inactive 004782,610 121601 Inactive 004782,610 121601 Inactive 004782,610 121601 Inactive 004782,611 121601 Inactive 0047	<u> </u>	7117	797,108,80	Gillona	101111	00,007,100	7	897	Palindrome Fix
B02-04 RE US 60/18/2,454 2/15/00 Inacilive 60/18/2,454 60/204 RE US 06/366,081 60/290 Pending 60/366/081 60/366/081 60/366/081 60/366/081 60/366/081 60/366/081 60/366/081 60/36/084 60/36/084 60/		<u> </u>			7/17/04	09/907 787		815-04	of Analytes
B02-04 RE	02	1/9,	002/146/00	AKIPO III	1000	000 0 1 p			System and Apparatus for Sequential Processing
B02-04 RE		•	501047 app	130	1/g/ng/	60/347 298	US	904P	
B02-04 RE US 69/182,464 2/1500 Inactive 60/182/464 802-06 US 09/052,816 3/31/98 Inactive 09/052/816 8/28 US 09/052,816 3/31/98 Inactive 09/052/816 8/28 US 09/052,212 8/10/00 Inactive 09/052/212 8/26-03P US 09/052/1058 8/21/00 Inactive 09/052/1058 8/22/00 Inactive 09/052/1059 Inactive 09/052/	100	1, 2,40	000001,0000		1				Identification of Genes Associated With Growth in
B02-04 RE US 60/182,464 2/15/00 Inactive 60/182,464 80/18	1	5	000 755/60	Pending	8/21/01	09/934,020	S	826-03	Polymorphic DNA Fragments and Uses Thereof
B02-04 RE US 09/366,081 2/15/00 Inactive 60/162/454 2/15/00 Inactive 60/162/454 4/15/00 Inactive 09/366,081 1/15/00 Inactive 09/366,571 1/15/00 Inactive 09/346,571 1/15/00 Inactive 09/341,030 1/15/00 Inactive 09/341,031 1/15/00 Inactive 09/341,031 1/15/00 Inactive 09/341,031 1/15/00 Inactive 09/341,031 1/15/00 Inactive 09/341,499 1/15/00 Inactive 09/341,396 1/15/00	/O1	1,58	09/756,830	Pending	1/8/01	09/56,830	57	010-02	and of minors of Cultural Country (1965)
B02-04 RE	198	10/5	60/103;030	Inaclive	10/5/98	60/103,030	5 5	See ore	
B02-04 RE	/02	1/9	60/347,396	Inactive	1/9/02	60/347,396	동	905P	
B02-04 RE	F		lands a		-				Cell Surface Polypeptides Affected
B02-04 RE	<u> </u>		60/347/286	hadive	1/9/02	60/347,286	S	902P	During Adipagene
B02-04 RE	16.1		000000000	O Principal in					Genes Affected by Cholesterol Treatment and
802-04 RE US 09/356,081 2/15/00 Inactive 60/182,454 09/366,081 09/366,081 60/182,454 09/366,081 09/366,212 09/	- T	n 3	09/962:610		5/23/97	08/862.610	ા	808-1	Ligation of Encoded Adpators
B02-04 RE	701	12/28	60/344,499	Abandone	12/28/01	60/344,499	S	4706	<u> </u>
orting Polynucleotides BOZ-04 RE US 60/182/454 (2/15/00) [hacdive] 60/182/454 (2/15		i i							
Ides 602-04 RE US 60782,454 2/15/00 nactive 60/182,454 4 Identification 802-04 RE US 09/366,081 8/2/90 Pending 09/366,081 09/366,081 Identification 802-06 US 09/052,816 3/31/98 Inactive 09/052,816 09/052,817 <td><u> </u></td> <td>12/18</td> <td>60/341,973</td> <td>Abandone</td> <td>12/18/01</td> <td>60/341,973</td> <td>SU</td> <td>901P</td> <td>Alherosclerosis Su</td>	<u> </u>	12/18	60/341,973	Abandone	12/18/01	60/341,973	SU	901P	Alherosclerosis Su
Identification 802-04 RE US 09/366,081 8/2/99 Pending 09/366,081 6/2/99 Pending	101		- 000	, income	1				Identification of Candidate Genes for the
Column	480	2000	60/344.034	nactivo	12/11/01	60/341,031	SU	903P	Genetic Analysis of Gene Expression
B02-04 RE US 09/366,081 2/15/00 Inactive 60/182,454 2/15/00 Inactive 60/182,454 602-04 RE US 09/366,081 60/2/99 Pending 09/366,081 09/366,081 60/2/99 Pending 09/366,081 09/366,0	Ò	<u></u>	DR/436 OR4	inaclive	5/8/95	08/436,084	S	804-01	Extension
B02-04 RE US 09/356,081 2/15/00 Inactive 60/182,454 2/15/00 Inactive 60/182,454 60/290 Pending 09/366,081 6/2/99 Pending 09/366,081 Pending 09/366,081 Pending 09/366,081 Pending 09/366,081 Pending 09/366,081 Pe	195	58	08/436,528	Abandone	56/8/6	V0/430,528	5	0	
B02-04 RE US 09/366,081 2/15/00 Inactive 60/182,454 2/15/00 Inactive 60/182,454 60/299 Pending 09/366,081 60/299 Pending 09/366,081 60/299 Pending 09/366,081 60/328 60/327,816 3/31/98 Inactive 09/052,816 828 US 09/636,212 8/10/00 Inactive 09/636,212 60/227,058 8/21/00 Inactive 60/227,058 8/21/00 Inactive 60/227,058 8/21/00 Inactive 09/346,571 7/13/93 Inactive 09/346,571 60/341,030 12/11/01 Abandone 60/341,030 1					T 5		 -	SULLING	Primers
B02-04 RE US 09/366,081 2/15/00 Inactive 60/182/454 2/15/00 Inactive 60/182/454 2/15/00 Inactive 60/182/454 6/2/99 Pending 09/366/081 6/2/99 Pending 09/052/816 Pending 09/	701	12/11	460/341,030	Abandone	LOPULZI	Aco't temo	C	5	NA Semience Analysis By Stringency Class
Section Boz-04 RE US 09/366,081 2/15/00 Inactive 60/182,454 2/15/00 Inactive 60/182,454 60/290 Pending 09/366,081 6/2/99 Fending 09/052,816	<u> </u>	•		•		מכנו לג כלומם	ñ	9069	Expression –
802-04 RE US 09/366,081 2/15/00 Inactive 60/182,454 802-04 RE US 09/366,081 6/2/99 Pending 09/366,081 802-06 US 09/652,816 3/31/98 Inactive 09/052,816 828 US 09/636,212 8/10/00 Inactive 09/636,212 826-03P US 60/227,058 8/21/00 Inactive 60/227,058 825 US 09/346,571 7/1/99 Inactive 09/346,571	V93	7/13	08/091,603	Mactive	CREELLY	000001,0000	2		ethod for the Analysis of Differential Gene
bynucleotides B02-04 RE US 60/182,454 2/15/00 Inactive 60/182,454 orring and Identification 802-04 RE US 09/366,081 6/2/99 Pending 09/366,081 orring and Identification 802-06 US 09/052,816 3/31/98 Inactive 09/052,816 and Method 828 US 09/636,212 8/10/00 Inactive 09/636,212 ts and Uses Thereof 826-03P US 60/227,058 8/21/00 Inactive 60/227,058 Inactive 09/346,571 7/1/99 Inactive 09/346,571					72000	naringa ens	ā	804	NA Sequencing by Random Primer Extension
802-04 RE US 09/366,081 2/15/00 Inactive 60/182,454 902-04 RE US 09/366,081 6/2/99 Pending 09/366,081 902-06 US 09/052,816 3/31/98 Inactive 09/052,816 928 US 09/636,212 8/10/00 Inactive 09/636,212 826-03P US 60/227,058 8/21/00 Inactive 60/227,058	799	7/1	09/346 571	ᆱ	7/1/99	09/346,571	SU	825	Polynucleotides by Chemic
802-04 RE US 09/366,081 8/2/99 Pending 09/366,081 09/366,081 8/2/99 Pending 09/366,081 09/052,816 3/31/98 Inactive 09/052,816 09/052,816 3/31/98 Inactive 09/052,816 09/052,816 3/31/98 Inactive 09/052,816 09/052,816 9/2/100 Inactive 09/636,212	000	12/8	000,12780	7	1100				Formation of Solid-Phase Arrays of
95 802-04 RE US 09/366,081 8/2/99 Pending 09/366,081 entification 802-06 US 09/652,816 3/31/98 Inactive 09/652,816 8/2/99 Inactive 09/652,816 9/052,816 9/052,816 9/052,816 9/052,816	5	3	and recina	מר	- AZZIAN	60/227.058	- S	826-03P	Polymorphic DNA Fragments and Uses Thereof
95 802-04 RE US 09/366,081 8/2/99 Pending 09/366,081 entification 802-06 US 09/052,816 3/31/98 inactive 09/052,816	A00	8/10	09/636,212	Inactive	8/10/00	09/636,212	5	020	Political party and an angel of the second s
802-04 RE US 09/366,081 6/2/99 Pending 09/366,081	198	3/31	91P/Zonren	пасиче	000100	00000000	5 6	979	ectrophoresis Apparatus and Method
802-04 RE US 09/366,081 8/2/99 Pending 09/366,081			5		3 171 / 100	09/052 816	<u></u>	802-06	Oligonucleolide Tags for Sorting and Identification
US 60/182,454 2/15/00 hadiye 60/182,454	9667	- B/2	09/366,081	Pending	6/2/99	09/366,081	S	B02-04 KE	Sanious of country of indicates
		245	60/182,454	Inactive	2/15/00	60/182,454	US	833P	Compositions for Soding Polymelectides

Dead Subset FOCSION	2	5							
DNA Restriction Site Mapping	845-03	<u> </u>	00/5/0 740	111	To be filed				
"Curvetle" sequencing	842	2 2	104040,140	DO/16176	Granted	09/549/748	4/14/00	4/14/00 6,720,179	4/13/04
Planar Arrays of Microparticle-Bound	i	5			To be filed	-			
Polynucleolides	815 US-C	<u>.</u>	10/19/ 89/	I I DIOO	J	1			
Method for Detecting Foreign DNA in a Host		18	100 124 no+	70,001,78	9/ (Subject of France)	10/124/884	4/18/02		
Genome	1004P	S	60/390 563	201100	1	2			
Method for Determining Relative Abundance of			0000000000	DRIII ZOVI ZVO	- SAIRDREIII	59C/085.mg	6/21/02		
Nucleic Acid Se	832-01	<u></u>	09/967 238	0.77/114	Dondina	20002			
Identification of Candidate Genes for the			00,00	10/17/0	Bulbita Louzie	D87 708/RO	9/27/01		
Alherosclerosis Su	901	55	10/322.774	19/17/00		7 1 CC C C C C C C C C C C C C C C C C C))		
Method for Applying a pH Gradient to a			1 1 (120 001	Billing Joseph	Filmia	10/322,774	12/17/02		
Microchannel Device	1000	<u></u>	10/322 000	10/17/00	Dianalina Alina	dolara oss			
Identification of Genes Associated With Growth in			1 0000	fillipina 1 Zotz r a i	1 810119	10/322,000	12/17/02		
Plants	904	S	10/338 777	17/m	17/03 Dending	10/228 777	ì		
Genes Affected by Cholesterol Treatment and			-	.,,,,,	2	10,000,777	501711		
During Adipogene	902	S	10/339,793	1.81.03	1/8/03 Pandino	10/330 703			
Identification of Specific Biomarkers for Breast			-		e de la company	100000,700	SO/B/L		
Cancer Cell	900	us S	10/339.782	1.8.0.3	1/8/03 Pending	10/330.783	5		
Secreted and Celt Surface Polypeptides Affected					9	70.1900.01	En/a/I		
By Cholester	905	S	10/340,192	1,18,103	1/8/03 Pending	10/340,192	1/8/03		
Polymorphic DNA Fragments and Uses Thereof	826-02 US	5	09/914 101	2/16/00	9/16/00 Danding	00004.304			
Pit beads with xfer	837	S.	_	<u>.</u>	inactive	00017,101	2/10/00		
Polymorph, Detections	831	S			inactive				
Hag sequencing	829	รย			Inactive				
Solid ph sed Iransfer w/RNA ampl	824	S			liactive	-			
Method for Applying a pH Gradient to a	-								
Microchannel Device	1003P	US	60/341,916	12/18/01 Inactive	Inactive	60/341,916	12/18/01		
Identification of Specific Biomarkers for Breast	•						i		
Cancer Cell	900P	S	60/348,053	1/9/02	Abandone	1/9/02 Abandone 60/348,053	1/9/02		
Massivery Parallel Signature Sequencing by		5	,						
Oligonucleofide Clamps Having Diagnostic	000	5	00000000	0 (Z/30 III ac)	Macuve	786,689,997	8/12/96		
Applications	904	<u></u>	00/097 397	7/5/03 0000	Oranine .	7007.707	5		
DNA Sequencing by Stepwise Ligation and	;			1100	Cianto	ourour, June	772/93	112/93 54 (3060	12/5/95
Cleavage	801-02 (SLC2)	S.	08/280.441	7/25/94 Grant	Granled	09/280 4/4	1		; ; ;
Convergent Synthesis of Branched Multiply	-		1	11000	Challten	00/200/44	//25/94	1125/84/5552278	96/2/6
Connected Macromolecular structures	003-01	ଞ	08/455,627	5/31/95 Gran	<u>E</u>	08/455 697	h 5	-	Ī
						201,000,000	Mol Jeelean en	1101100	11000

F.	<u> </u>	기=	10	10	- 't	· · ·	п	0	>	Ū	Ta	π÷	C	ilo		<u> </u>	0	(c	ΣÌ⊒		i iii	· C	া ভ	3	工	0	10	Z	ľ	٥	10) C	기독	C	i C
i ivajaniam	Solid Phase Synthesis of Oligonucleotide N3'->P5'	Inerapeulic Applications	Oligonucleotide Clamps Having Diagnostic and	DNA Extension and Analysis with Rolling Primers	Polynucleotides	Simulaneous Sequencing of Tagged	Extensions	DNA Sequencing By Parallel Oligonucleolide	Amplification Using C	Polynucleotide Detection by Isothermal	Oligonucieolide Clamps		Oligodeoxyribonucleotide N3' P5'	Cleavage	DNA Sequencing by Stepwise Ligation and	Phosphoramidates	Oligo-2' -Fluoronucleotide N3'->P5'	Compositions for Sorting Polynucleolides	modified internuc	Process for making oligonucleotides having	inkages	Oigonucleotides having modified internucleoside	lags	Minimally cross-hybridizing sets of oligonucleotide	Hybridization and	Oligonucleolide N3'->P5' Phosphoramidates:	Olignudeotide Tag	Methods for Sorting Polynucleotides Using	Hybridization and nuclease resistance properties	Oligonucleotide N3'->P5' Phosphoramidates:	Стванаде	DNA Sequencing by Stepwise Ligation and	Inplex DNA	Oligonucleolide N3.fwdanw.P5' phosphoramidates:	Compounds
035-01		004-02		811	807		805	•	806		004-01	006-01		801-06 (SLC4)		035-00		802-04	9213 DIV C		9213 DIV B		802-03		005-03		802-02		005		801-05 (SLC3)		005-02		0012-00
S		S	-	CS.	SI		SU		S		SU	US.		Sh		S.		S	S		S		S		SP		S		Ę.		S		SiO		S
08/663,918		08/713,685	ļ	08/611,155	08/560,313		00/424,663	,	08/536,743		08/461,271	08/465,368		08/667,689		08/603,566		08/484,712	08/467,219		08/471,248		08/478,236		08/473,015	1	08/358.810		214599		08/410,116		08/478,470		666,680/80
6/14/96		9/17/96 Grad		3/5/96 Gra	11/17/95 Grai		4/17/95		9/29/95		6/5/95	6/5/95 Grar		621/96		2/21/96		6/7/95	6/6/95		96/9/9		6/7/95 Grau		66695		12/19/94 Gran	4	3/18/94 0/2		3/24/95 Gra		6,6795		7/9/93 Gra
6/14/96 Granted		Granled		Granled	Granted		4/17/95 Granted		9/29/95 Granted		<u> </u>	Granted		6/21/96 Granted		2/21/96 Granted		Granter	Granted		6/6/95 Granted		Granted		Granted	Cicinos	Granled	Cichino			Granted		6/6/95]Granted	0101100	
08/663,918	1000	08/713,685	- 1,000	08/611/155	08/560,313		08/424.663	0	DR/536 743	00,101,67	OR/AR1:071	08/465,368		08/667,689	- 500	08/603 566		DAMARA 719	08/467/219		08/471 248	1	08/478.238	3.100	08/473.015	00000000	09/359.910	1100	214500		08/410,116		08/478/470	00,000,000	nachad ooo
6/14/96 5824793	0677100 007710	907710	Sperior.	2/2/202	11/17/95 5763175		4/17/05 57509/4	0021410 0016216		DB/GH	00000	2505 2505	012 1300 OF 14000	80100	C#1 B00 C 06 01 247	33166	081110	67706	i 56/9/9	20,00	2012/2	91100	90/7/9	CEMIN	2000	760409C 45181771	43/40/04	56701AC	011001		3/24/95	0,0,30	ממ	ERRY	1
5824793	0677100	1017705	PCZ00 45 Bernin	20000	5763175	47 000 47	5750344	0747200	2000	C401476 D87640	C744040	6/5/95 5726297	4000	574 A320	CAT BOOK	F F F F F F F F F F F F F F F F F F F	0//80 0004410	5054449	6/6/95 5648480	ODZOMO CEOM	nereken	977400	5835400	CC1 100C CENTO	100 H 100	JOHU9/	200	2ZEEGCC 162017C	100000		3/24/95 5599675	Outsclosure	504607	VANA 92/1803	
10/20/98	BEADOL		BR/b1.//	-	96/6/9	01 1230	511200	55/5/5	7	4/21/98	0800370	140/09	06/6/7	2500	76#711		1819AP	01000	744500	78/01/7	7110101	Jakero	5 5 7 7	/6m7/c	7	718/97		16/5/2	-		2/4/97	18/1/1	3	11/5/96	

Page

On and Bit -04 (SLC3C2) US 08/98/9.866 6/15/96 Granted Granted 08/98/9.866 8/15/96 8/39/658 8/15/96 8/	Convergent Synthesis of Branched Midlight									
801-04 (SLC3C2) US 084712,011 9/1198 Granted 084712(011 9/1198 5831658 005-01 US 084712,011 9/1198 Granted 08478,233 06498 5837835 1 032-05 US 08468,453 06478,233 06898 Granted 08478,233 06498 5846719 005-02 US 08478,233 12/2006 Granted 08478,233 17686 5846719 005-02 US 08478,233 12/2006 Granted 08478,105 08771,789 12/2006 5846719 005-02 US 08478,235 12/2006 Granted 08478,105 08771,789 12/2006 5846719 005-02 US 08478,235 12/2006 Granted 08478,105 08771,789 12/2006 5846719 005-02 US 08478,236 12/2006 Granted 08478,105 08779,5883732 005-02 US 08478,266 12/2006 Granted 08485,105 08/202,286 12/1904 5883722 005-02 US 08478,266 12/2006 Granted 08/20,266 12/2006 5885934 11/207 5865720 12/2006 5885934 11/207 5865720 12/2006 5885934 11/207 5865720 12/207		003-02	SU	08/689,856	96/51/8	Granlad	09/690-656		_	
801-04 (SLC3C2) U.S 084712,011 9/1196 Granked 08712,011 9/1196 5831085 005-01 U.S 08477,306 6839,453 8886 Granted 08478,238 9/1395 5837835 1 085-02 U.S 084678,239 7/895 Granked 08478,238 7/895 58583722 U.S 08478,739 12/20096 Granked 08478,238 7/895 58583723 1 085-02 U.S 08465,105 9/1395 Granked 08445,105 9/1395 5853733 1 085-02 U.S 08465,105 9/1395 Granked 08445,105 9/1395 5853737 1 085-02 U.S 08465,105 9/1395 Granked 08445,105 9/1395 5853737 1 085-02 U.S 08466,120 9/1395 Granked 08455,105 9/1395 5853737 1 085-02 U.S 08466,120 9/1395 Granked 08455,105 9/1395 5853737 1 085-02 U.S 08466,120 9/1395 Granked 08455,105 9/1395 5853737 1 085-02 U.S 08466,120 9/1395 Granked 08465,120 9/1395 5853737 1 085-02 U.S 08466,138 1 07/97 Granked 08472,446 9/1395 5865720 1 085-02 U.S 08466,138 1 07/97 Granked 08472,446 9/1395 5865720 1 085-02 U.S 08466,138 1 07/97 Granked 08704,041 57298 673465 1 08704,041 57298 673465 1 08704,041 1 08708,043 1 08707,477 4 4/3098 673464 09/076,477 4/3098 673465 1 08708,138 1 07/97 673465 1 08708,138 1 07/97 673465 1 08708,138 1 087	Ligation and		,	000,000	0610140	Cialibi	08/689/890	8/15/96/58306) Š	11/3/98
005-01 US 084477,306 6/8/85 Granted 08477 306 8/8/95 5887835 1 005-05 US 08669,453 6/8/96 Granted 08469,453 8/6/66 5846719 801-03 (SLC3C1) US 08669,453 6/8/96 Granted 08478,239 7/8/95 588693 005-02 US 08471,789 1220096 Granted 08478,239 7/8/95 588693 005-02 US 08465,105 97795 Granted 08445,105 67796 588692 803-01 US 08669,924 6/7/96 Granted 08445,105 67796,5886923 814 US 08669,924 6/7/96 Granted 08455,924 6/7/96 5883722 9213 DIVE CPA US 08669,924 6/7/96 Granted 08455,924 6/7/96 5883727 9213 DIVE CPA US 08669,924 6/7/96 Granted 08455,924 6/7/96 5893727 9213 DIVE CPA US 08669,924 6/7/96 Granted 08455,924 6/7/96 5893727 9213 DIVE CPA US 08669,924 6/7/96 Granted 08455,924 6/7/96 5893727 9213 DIVE CPA US 08669,924 6/7/96 Granted 08455,924 6/7/96 5992718 814 1US 08669,924 6/7/96 Granted 08455,924 6/7/96 5992718 818 11-01 US 08672,466 6/1097 Granted 08476,120 8/22/97 5992728 818 11-01 US 08672,466 6/1097 Granted 08700,448 1/1097 5992728 818 11-01 US 08693,431 107/97 Granted 08704,041 5/22/98 6/7/96 5998604 818 005-05 US 08964,138 107/97 Granted 08704,041 5/22/98 6/7/97 5998674 818 005-05 US 08963,138 107/97 Granted 08704,041 5/22/98 6/7/97 5998674 818 005-05 US 08963,138 107/97 Granted 08704,041 5/22/98 6/7/97 5998674 818 005-05 US 08963,533 11/898 Granted 08705,477 4/30/98 6/7/97 5998674 818 005-05 US 08969,533 11/898 Granted 08705,477 4/30/98 6/7/97 59986774 818 005-05 US 08969,533 11/898 6/38977 11/898 6/3		801-04 (SLC3C2)	SU	08/712,011	9/11/96	Granted	08/712/011	9/11/96/58310	<u> </u>	<u>.</u>
005-01 US 08477,306 66985 Granted 08477,306 08495 5837835 005-05 US 084659,453 86986 Granted 08477,306 08495 5837835 801-03 (SLC3C1) US 08478,239 7695 Granted 08478,239 7695 5856093 803-02 US 08478,239 7695 Granted 08477,789 122096 Granted 08477,789 122096 585923 803-01 US 08485,105 04795 Granted 08475,105 67795 585823 803-01 US 08485,286 1271994 Granted 08482,608 471597 5888737 814 US 08485,924 97795 Granted 0865,924 67796 586223 811-01 US 08485,922 97797 Granted 0865,924 67798 5888737 815 005-05 US US 08472,026 97787 Granted 0865,924 471597 5888722 818 005-01 US 08472,026 971587 Granted 08672,044 171097 586228 819 US 08472,026 971587 Granted 08472,446 <t< td=""><td>Oligonucleotide N3'->P5' Phosphoramidales:</td><td></td><td></td><td>"</td><td></td><td></td><td></td><td></td><td>1</td><td> =</td></t<>	Oligonucleotide N3'->P5' Phosphoramidales:			"					1	=
B02-05 US D8/659,453 D6/8/96 Granted D8/659,453 D6/8/96 B948719		005-01	Su	08/477,306	6/6/95	Granted	08/477 306	6/6/95 58378		<u> </u>
801-03 (SLC3C1) US 08476,739 77695 Granhed 08478,239 77695 5856093 0.35-02 US 084771,789 1220056 Granhed 084771,789 1220069 5856093 803-01 US 08485,105 64785 Granhed 08485,105 64795 5853722 803-01 US 08485,105 64785 Granhed 08485,105 64795 5853722 803-01 US 08485,268 41597 Granhed 08842,608 41597 5863722 811-01 US 08485,120 82297 Granhed 08916,120 82297 5962228 811-01 US 08492,608 411097 Granhed 08916,120 82297 5962228 805-05 US 08492,620 911697 Granhed 08922,44 647987 5962228 806-07 US 08492,620 911697 Granhed 08922,24 647987 5962228 806-07 US 08492,620 911697 Granhed 08922,24 647987 5962228 806-07 US 08492,620 911697 Granhed 08922,24 647987 5962228 806-07 US 08492,620 911697 Granhed 08926,720 911697 5998604 806-07 US 08492,621 911699 Granhed 08926,720 911697 6998604 806-07 US 08492,621 911699 Granhed 08946,138 107797 6998604 806-07 US 084946,138 107797 Granhed 08946,138 107797 6998604 806-07 US 08498,543 11/2098 Granhed 08946,543 11/2098 6136077 806-07 US 08498,543 11/2098 Granhed 08946,543 11/2098 6136077 806-06 US 08498,543 11/2098 Granhed 08496,543 11/2098 61360516		302-05		DRJ650 453	8(8)08	Control			-	
803-03 US 08478,739 77635 Granted 08478,239 77635 5856093 035-02 US 08475,789 122036 Granted 084771,789 122036 5859233 803 US 08465,105 67795 Granted 08485,105 67795 5863722 803-01 US 08359,295 1271934 Granted 08482,608 4/15397 5883737 811-01 US 083916,120 822397 Granted 08482,608 4/15397 5883737 8213 DIVE CPA US 083916,120 822397 Granted 08482,608 4/15397 5862228 805-01 US 08492,608 4/15397 Granted 08482,608 4/15397 5862228 805-01 US 08492,620 9/15497 Granted 084916,120 8/22397 5862228 808-01 US 08492,620 9/15497 Granted 08492,620 9/15497 5866720 808-2 US 08493,041 5/2238 Granted 08493,138 104797 6013445 004-03 US 084946,138 104797 Granted 08492,623 14698 6048974 805-03 US 084946,138 104797 Granted 08492,623 14698 6048974 805-03 US 08493,236 14699 Granted 08492,623 116498 613677 805-03 US 08493,365 1403098 Granted 08493,560 1033098 6136977 805-03 US 08493,365 1403098 Granted 08493,560 1033098 6136977 805-05 US 08493,386 04493 613616 08493,560 1033098 6136977 805-06 US 08493,386 04493 613616 08493,560 11623098 613657				0000	Ocholo	CHAILLEC	V01009;453	6/6/96 58467		12/0/98
035-02 US 08/71,789 12/20/96 Granted 08/71,789 12/20/96 5859233 803 US 08/485,105 08/71,789 12/20/96 5859233 803-01 US 08/359,295 12/19/94 Granted 08/359,295 12/19/94 5695934 56959		901-03 (SLC3C1)	SU	08/478,239	7/6/95	Granted	08/478 239	7/8/05 50560	3	
035-02 US 09/771,789 12/20/96 Granled 08/771,789 12/20/96 5859/233 803 018 09/465,105	Synthons for Synthesis of Oligonucleo(ide N3-P5	,						00000	19	=
803 US 09/465,105 07/95 Granted 08/45,105 67/95 5863722 803-01 US 09/359,295 12/19/94 Granted 08/45,105 67/95 5863722 803-01 US 09/359,295 12/19/94 Granted 09/359,295 12/19/94 5895934 814 US 09/359,2608 41/5/97 Granted 09/359,295 41/5/97 5888737 9213 DIVE CPA US 09/359,224 09/796 Granted 09/359,924 67/96 5832718 811-01 US 09/359,224 09/796 Granted 09/359,924 67/96 5832718 805-01 US 09/359,620 9/15/97 Granted 09/359,620 9/15/97 5965720 805-01 US 09/972,446 6/10/97 Granted 09/379,446 9/10/97 5965720 806-03 US 09/364,041 5/22/98 Granted 09/329,620 9/15/97 5998604 818 US 09/370,477 4/30/98 Granted 09/380,543 11/30/98 Granted)36-02	SU	08/771,789	12/20/96		08/771-780	12/20/00 50502		
803-01 US 08/359,295 12/19/94 Granted 08/359,295 12/19/94 56985934 8114 US 08/859,924 6/17/96 Granted 08/859,924 6/17/96 59985934 9213 DIVE CPA US 08/859,924 6/17/96 Granted 08/859,924 6/17/96 5998737 9213 DIVE CPA US 08/859,924 6/17/96 Granted 08/916,120 8/22/97 5968737 9213 DIVE CPA US 08/859,924 6/17/96 Granted 08/916,120 8/22/97 5968737 9213 DIVE CPA US 08/859,924 6/17/96 Granted 08/916,120 8/22/97 5968737 9213 DIVE CPA US 08/859,924 6/17/96 Granted 08/916,120 8/15/97 5968729 9213 DIVE CPA US 08/959,924 6/17/96 Granted 08/916,120 8/15/97 5968729 9213 DIVE CPA US 08/959,924 6/17/96 Granted 08/916,120 8/15/97 5968729 9213 DIVE CPA US 08/959,924 6/17/96 Granted 08/916,120 8/15/97 5968729 9213 DIVE CPA US 08/959,924 6/17/96 Granted 08/916,120 8/15/97 5968729 9213 DIVE CPA US 08/959,924 6/17/97 Granted 08/916,120 8/15/97 5968729 9213 DIVE CPA US 08/959,620 9/15/97 Granted 08/970,446 6/10/97 5965720 9213 DIVE CPA US 08/959,639 10/7/97 Granted 08/959,620 9/15/97 5965720 9213 DIVE CPA US 08/959,639 10/7/97 Granted 08/959,639 10/7/97 6/13/65 9213 DIVE CPA US 08/959,639 10/7/97 Granted 08/959,639 10/7/97 6/13/65 9213 DIVE CPA US 08/959,939 10/7/97 Granted 08/959,639 10/7/97 6/13/65 9213 DIVE CPA US 08/959,939 10/7/97 Granted 08/959,639 10/7/97 6/13/65 9213 DIVE CPA US 08/959,939 10/7/97 Granted 08/959,639 10/7/97 6/13/65 9213 DIVE CPA US 08/959,939 10/7/97 6/13/65 9213 DIVE CPA U		103	S	08/485 105	6/7/05	Granlad	09/405 405	78C0C(08/07/7)		15
803-01 US 08/95,285 12/19/94 Granted 08/359,295 12/19/94 5695934 814 US 08/942,568 4/15/97 Granted 08/942,608 4/15/97 5898737 9213 DIVE CPA US 08/959,924 6/7/96 Granted 08/959,924 6/7/96 5932718 811-01 US 08/970,448 1/10/97 Granted 08/970,448 1/10/97 5962228 805-01 US 08/972,446 6/10/97 Granted 08/972,446 8/10/97 5965720 805-01 US 08/929,620 9/15/97 Granted 08/928,620 9/15/97 598604 818 US 09/084,041 5/22/98 Granted 08/928,620 9/15/97 598604 818 US 09/084,041 5/22/98 Granted 08/928,620 9/15/97 598604 808-2 US 09/084,041 5/22/98 Granted 08/928,620 9/15/97 5998604 8045-01 US 09/928,128 10/7/97 Granted 09/928,128 10/7/97 6013445 8045-01 US 09/928,128 2/23/98 Granted 09/928,128 2/23/98 6048974 845-02 US 09/187,783 11/6/99 Granted 09/187,793 11/6/99 6136537 802-11 US 09/089,853 6/3/98 Granted 09/183,650 10/30/98 6136537 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6136537 805-06 US 08/923,346 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6140469 805-06 US 08/923,346 09/93,346 09/183,650 10/30/98 6140469				000	9.700	Clouison	COLICOPIDO	6//95 58637		慧
8144 US 08/842,508 4/15/97 Granted 08/842,608 4/15/97 5888737 9213 DIVE CPA US 08/859,924 6/7/96 Granted 08/859,924 6/7/96 5932718 8111-01 US 08/859,924 6/7/96 Granted 08/816,120 8/22/97 5962228 805-05 US 08/970,448 1/10/97 Granted 08/970,448 1/10/97 5965720 805-01 US 08/972,446 6/10/97 Granted 08/970,448 1/10/97 5965720 808-2 US 08/924,041 5/22/98 Granted 08/929,620 9/15/97 5998604 818 US 08/946,138 10/7/97 Granted 08/948,138 10/7/97 6013345 004-03 US 09/094,138 10/7/97 Granted 08/948,138 10/7/97 6013445 004-03 US 09/070,477 4/30/98 Granted 08/948,138 10/7/97 6013445 845-01 US 09/070,477 4/30/98 Granted 08/970,477 4/30/98 6048974 845-02 US 09/089,853 11/6/98 Granted 08/989,353 11/6/98 6138537 803-03 US 09/183,650 10/30/98 Granted 08/989,553 6/3/98 6138077 803-03 US 09/186,543 11/20/98 Granted 08/989,553 6/3/98 6138077 803-05 US 09/186,543 11/20/98 Granted 08/989,553 6/3/98 6138077 805-06 US 09/186,543 11/20/98 Granted 08/989,553 6/3/98 6138077 805-06 US 09/186,543 11/20/98 Granted 08/989,553 6/3/98 6138077		303-01	SU	08/359 295	19/10/07	Granlad	00/250 ONE			
9213 DIVE CPA US 08/859,924 6/7/96 Granted 08/859,924 6/7/96 5932718 9213 DIVE CPA US 08/859,924 6/7/96 Granted 08/859,924 6/7/96 5932718 811-01 US 08/916,120 8/22/97 Granted 08/916,120 8/22/97 5963228 805-05 US 08/92,446 6/10/97 Granted 08/970,448 1/10/97 5969119 038-00 US 08/92,446 6/10/97 Granted 08/972,446 6/10/97 5969119 808-2 US 08/946,138 1/7/97 Granted 08/929,620 9/15/97 5988604 808-2 US 08/946,138 10/7/97 Granted 08/929,620 9/15/97 6013445 808-2 US 08/946,138 10/7/97 Granted 08/929,620 9/15/98 6013445 808-2 US 08/952,128 2/23/98 Granted 08/070,477 4/30/98 6048974 808-11 US 08/958,853 11/6/98 Granted 09/183,650 10/30/98 6138637 809-13 US 08/183,650 10/30/98 Granted 09/183,650 10/30/98 6138077 8005-06 US 08/953,386 07/307 Granted 09/196,543 11/20/98 6138077	n Adaptor-Based Sequence			-	10,00	Clane	062,666,000	12/19/94 56959		2
9213 DIVE CPA US 08/859,924 6/7/96 Granted 08/859/924 6/7/96 5932718 811-01 US 08/916,120 8/22/97 Granted 08/916,120 8/22/97 5962228 805-01 US 08/972,446 6/10/97 Granted 08/970,448 1/10/97 5962228 805-01 US 08/972,446 6/10/97 Granted 08/972,446 6/10/97 5969119 038-00 US 08/929,620 9/15/97 Granted 08/972,446 6/10/97 5998604 818 US 09/084,041 5/22/98 Granted 08/929,620 9/15/97 5998604 808-2 US 09/084,041 5/22/98 Granted 08/946,138 10/7/97 6013445		314	S	กลเลสว รณล	diagno	Omniad	5			
9213 DIVE CPA US 08/859,924 6/7/96 Granted 08/659,924 6/7/96 5932718 811-01 US 08/916,120 8/22/97 Granted 08/916,120 8/22/97 5962228 805-05 US 08/970,448 1/10/97 Granted 08/9700,448 1/10/97 5965720 805-01 US 08/972,446 6/10/97 Granted 08/972,446 6/10/97 5965720 818 US 09/084,041 5/22/98 Granted 08/929,620 9/15/97 5998604 818 US 09/984,041 5/22/98 Granted 08/929,620 9/15/97 5998604 808-2 US 08/946,138 10/7/97 Granted 08/924,041 5/22/98 6/013165 004-03 US 09/084,041 5/23/98 Granted 09/084,138 10/7/97 6/013445 004-03 US 09/070,477 4/30/98 Granted 09/076,477 4/30/98 6/04276 845-02 US 09/084,053 11/6/98 Granted 09/078,178 4/30/98 6/04276 845-02 US 09/187,793 11/6/98 Granted 09/088,128 2/23/98 6/04276 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6/38077 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6/138077	Novel Oligonucleolides Having Modified			1000	10,001	Charles	00042,000	4/15/97 58887		4/30/99
811-01 US 08/916,120 8/22/97 Granted 08/916,120 8/22/97 5962228 8005-05 US US 08/700,448 1/10/97 Granted 08/700,448 1/10/97 5965720 8005-01 US 08/972,446 6/10/97 Granted 08/872,446 6/10/97 5969119 038-00 US 08/929,620 9/15/97 Granted 08/929,620 9/15/97 5998604 818 US 08/946,138 10/7/97 Granted 08/929,620 9/15/97 5998604 808-2 US 08/946,138 10/7/97 Granted 08/946,138 10/7/97 6013/45 004-03 US 08/928,128 2/23/98 Granted 08/946,138 10/7/97 6013/45 845-01 US 08/928,128 2/23/98 Granted 08/028,128 2/23/98 6048974 845-02 US 09/187,793 11/6/98 Granted 09/081,793 11/6/98 6138077 802-11 US 08/98,853 6/3/98 Granted 09/183,650 10/30/98 6138077 803-03 US 09/186,543 11/20/98 Granted 09/183,650 10/30/98 6138077 802-13 US 09/186,543 11/20/98 Granted 09/183,650 10/30/98 6138077 805-06 US 08/923,386 61/30/97 Granted 09/186,543 11/20/98 6150516		213 DIVE CPA	SU	08/659,924	6/7/96	Granted	08/659,924	6/7/96 59327		₹
8005-05 US US 08/700,448 1/10/97 Granted 08/700,448 1/10/97 Se65720 805-01 US 08/872,446 6/10/97 Granted 08/872,446 6/10/97 J5969119 9038-00 US 08/929,620 9/15/97 Granted 08/929,620 9/15/97 J598604 818 US 08/929,620 9/15/97 Granted 08/929,620 9/15/97 J598604 808-2 US 08/946,138 10/7/97 Granted 08/946,138 10/7/97 G013445 004-03 US 09/070,477 4/30/98 Granted 08/946,138 10/7/97 G013445 845-01 US 09/028,128 2/23/98 Granted 08/070,477 4/30/98 Granted 845-02 US 09/187,793 11/6/98 Granted 09/187,793 11/6/98 Granted 802-11 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 G13653 802-13 US 09/186,543 11/20/98 Granted 09/186,543 11/20/98 G13650 802-13 US 09/186,543 11/20/98 Granted 09/186,543 11/20/98 G13650		311-01	LS.	08/916,120	8/22/97	Granted	08/916,120	8/22/97 59622		₫
805-01 US 08/872,446 6/10/97 Granted 08/872,446 6/10/97 5969119 038-00 US 08/929,620 9/15/97 Granted 08/029,620 9/15/97 5969604 818 US 08/946,138 10/7/97 Granted 08/029,620 9/15/97 5969604 808-2 US 08/946,138 10/7/97 Granted 08/0246,138 10/7/97 6013445 004-03 US 09/070,477 4/30/98 Granted 08/0246,138 10/7/97 6013445 845-01 US 09/028,128 2/23/98 Granted 08/028,128 2/23/98 6054276 845-02 US 09/028,128 2/23/98 Granted 09/028,128 2/23/98 6054276 802-11 US 09/089,853 6/3/98 Granted 09/187,793 11/6/98 6136537 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6138077 803-06 US 08/93,386 07/30/8 Granted 09/183,543 11/20/98 6150516)05-05 US	ā	08/700 4/AR	4/40/07	0				ļ
805-01 US 08/872,446 6/10/97 Granted 08/872,446 6/10/97 5969119 038-00 US 08/929,620 9/15/97 Granted 08/929,620 9/15/97 5969119 808-2 US 08/946,138 10/7/97 Granted 08/946,138 10/7/97 6013)45 808-2 US 08/946,138 10/7/97 Granted 08/946,138 10/7/97 6013)45 845-01 US 09/026,128 2/23/98 Granted 09/028;128 2/23/98 6048974 845-01 US 09/026,128 2/23/98 Granted 09/028;128 2/23/98 60542/76 845-02 US 09/089,853 11/6/98 Granted 09/187,793 11/6/98 6136537 802-11 US 09/089,853 6/3/98 Granted 09/183,650 10/30/98 6138077 803-03 US 09/183,650 10/30/98 Granted 09/196,543 11/20/98 613077 005-06 US 08/923,386 073/07 Granted 09/196,543 11/20/98 6150516			1	00,000	0.10501	General	007700,446	77097 59657		2
038-00 US 08/929,620 9/15/97 Granted 08/929,620 9/15/97 S998604 818 US 09/084,041 5/22/98 Granted 09/084/041 5/22/98 G013165 808-2 US 09/070,477 4/30/98 Granted 09/070,477 4/30/98 G054276 845-02 US 09/089,853 11/6/98 Granted 09/187,793 11/6/98 Granted 09/187,793 11/6/98 Granted 09/187,793 11/6/98 Granted 09/183,650 10/30/98 Granted 09/183,650 10/30/98 Granted 09/183,650 10/30/98 G138077 802-13 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 G140/489 11/20/98 G138077 805-06 US 09/183,653 10/30/98 Granted 09/183,643 11/20/98 G138077 11/20/98 G138077		305-01	S	08/872.446	6/10/97	Granted	08/879 AAG	2007		2
818 US 09/084,041 5/22/98 Granted 09/094;041 5/22/98 6013165 808-2 US 09/070,477 4/30/98 Granted 09/070,477 4/30/98 6013445 004-03 US 09/070,477 4/30/98 Granted 09/070,477 4/30/98 6048974 845-01 US 09/028,128 2/23/98 Granted 09/028,128 2/23/98 6054276 845-02 US 09/187,793 11/6/98 Granted 09/187,793 11/6/98 6136537 802-11 US 09/089,853 6/3/98 Granted 09/187,793 11/6/98 6138077 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6138077 803-03 US 09/186,543 11/20/98 Granted 09/196,543 11/20/98 6150516)38-00	જ	08/929.620	9/15/97	Granled	002.000/60	1,696C 16A1 M		ı
808-2 US 08/946,138 10/7/97 Granled 08/946,138 10/7/97 6013/45 004-03 US 09/070,477 4/30/98 Granted 09/070,477 4/30/98 6048974 845-01 US 09/028,128 2/23/98 Granted 09/028,128 2/23/98 6054276 845-02 US 09/187,793 11/6/98 Granted 09/187,793 11/6/98 6136537 802-11 US 09/089,853 6/3/98 Granted 09/187,793 11/6/98 6138077 803-03 US 09/186,543 11/20/98 Granted 09/196,543 11/20/98 6140/409 802-13 US 09/186,543 11/20/98 Granted 09/196,543 11/20/98 6150516		318	SU	09/084.041	SD2208	Granted	0.00,010,000	30000 20000 30000 1800 180	Ē	12
808-2 US 08/946,138 10/7/97 Granted 08/946,138 10/7/97 6013445 004-03 US 09/070,477 4/30/98 Granted 09/070,477 4/30/98 6048974 845-01 US 09/028,128 2/23/98 Granted 09/028,128 2/23/98 6054276 845-02 US 09/187,793 11/6/98 Granted 09/187,793 11/6/98 6136597 802-11 US 09/089,853 6/3/98 Granted 09/187,793 11/6/98 6136597 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6140489 802-13 US 09/186,543 11/20/98 Granted 09/196,543 11/20/98 6140489 005-06 US 08/923,386 07/307 Granted 09/196,543 11/20/98 6150516	Massively Parallet Signature Sequencing by					Ci ci ii ci	00001	15100 06/776	8	یا
004-03 US 09/070,477 4/30/98 Granted 09/070,477 4/30/98 Granted 09/070,477 4/30/98 G048974 845-01 US 09/028,128 2/23/98 Granted 09/028,128 2/23/98 G054276 845-02 US 09/187,793 11/6/98 Granted 09/187,793 11/6/98 Granted 802-11 US 09/089,853 6/3/98 Granted 09/089,853 6/3/98 Granted 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 Granted 802-13 US 09/186,543 11/20/98 Granted 09/183,650 10/30/98 Granted 905-06 US 08/923,386 07/927 Granted 09/186,543 11/20/98 Granted		308-2	SU	08/946,138	10/7/97	Granled	08/946_136	10/7/07 60434		i Z
004-03 US 09/070,477 4/30/98 Granted 09/070,477 4/30/98 Granted 09/070,477 4/30/98 G054276 845-01 US 09/028,128 2/23/98 Granted 09/028,128 2/23/98 G054276 845-02 US 09/187,793 11/6/98 Granted 09/187,793 11/6/98 Granted 802-11 US 09/089,853 6/3/98 Granted 09/089,853 6/3/98 Granted 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 Granted 802-13 US 09/186,543 11/20/98 Granted 09/186,543 11/20/98 Granted 005-06 US 08/923,386 07/927 Granted 09/196,543 11/20/98 Granted				,			04010,100	46100 267701		=
845-01 US 09/028,128 2/23/98 Granted 09/028,128 2/23/98 6054276 845-02 US 09/187,793 11/6/98 Granted 09/187,793 11/6/98 6136537 802-11 US 09/089,853 6/3/98 Granted 09/089,853 6/3/98 6138077 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6140/489 802-13 US 09/186,543 11/20/98 Granted 09/196,543 11/20/98 6150516		004-03	S	09/070,477	4/30/98	Granted	09/070:477	OBYUS BOALIST		
845-02 US 09/187,793 11/6/96 Granted 09/187,793 11/6/96 6136537 802-11 US 09/089,853 6/3/96 Granted 09/089,853 6/3/98 6138077 803-03 US 09/183,650 10/30/96 Granted 09/183,650 10/30/96 6140/469 802-13 US 09/186,543 11/20/98 Granted 09/196,543 11/20/98 6150516		345-01	SU	09/028,128	2/23/98	Granted	09/028/128	Craus Borecie		<u> </u>
802-11 US 09/089,853 6/3/98 Granted 09/089,853 6/3/98 6138077 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6140489 802-13 US 09/186,543 11/20/98 Granted 09/196,543 11/20/98 6150516		45-02	S	09/187,793	11,609.0	Granted	09/187/793	20012 00/2/11		3 2
803-03 US 09/183,650 10/30/98 Granted 09/089,853 6/3/98 6138077 803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6140489 802-13 US 09/186,543 11/20/98 Granted 09/196,543 11/20/98 6150516	Method, Apparatus and Computer Program						- 100	COCTO DEPORT	_	Į
803-03 US 09/183,650 10/30/98 Granted 09/183,650 10/30/98 6140489 6150516 09/5-06 US 08/923,386 9/3/07 Granted 09/196,543 11/20/98 6150516		302-11	SU	09/089,853	6/3/0A	Granled	00/000 053			;
802-13 US 09/196,543 11/20/98 Granted 09/196,543 11/20/98 6150516 005-06 US 08/923.386 0/3/07 Granted 09/196,543 11/20/98		103-03	ଞ	09/183.650	PONE SI	Granted	099,587,00	000000 0138U		12
005-06 US 08/923-386 0/3/07 Granted contract of 17/20/98 6150516		02-13	SU	09/196.543	11/20/09	Cranted	00000000	100000 014U4	 	돌
005-06 US 08/923 386 9/3/97/2/2016 100/023 306				1000	10000	otalitan	09(190,040	11/20/98 61505		15
)05-06 	S	UNIONA JAK	0/2/07					

	902-02 CA DIV	\$	2.441.634	10/12/05 Earl		-		
Massively Parallel Sequeniong of Sorted Polynucleotides	803 CB	3		10,167.00	J. Holl	2,441,034	10/12/95	
Methods for Identifying Genes Regulating Desired	000	ē	8383/322.6	10/12/95 Filed	Filed	95937322.6	10/12/95	_
Cell Phenotypes		<u>-</u>	69/263 907	tour cot] - -	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	:	
ŝ	819-01D	S 8	10V646 451	204271	Donding	68/263,807	1/24/02	
		5	10040,401	60/17/8	8/21/03 Pending	10/646,451	8/21/03	
	1004	PCT	PCT/US2003/	6/21/02	6/21/02 Pending	PCT/US2003/01	6/21/02	
Oligorucleotide Tags for Sorting and Identification	802-10	US ·	09/131,009	8/7/98	Granted	09/131,009	8/7/98 6172214	2214
Oligonudeolide Tags for Sorting and Identification	802-09	<u> </u>	nainas ssa	in i		0000		_
			000000	000	Panier	027,750,60	6/5/98/6172218	2218 1/9/01
	814-01	S	09/225,652	1/5/99 Gran	oranjer T	DODOR REO		
	818-01	S	09/448,908	11/23/99 Gran	Granted	09/448 009	710000 CO 10 CO 110	_
Measurement of Gene Expression Profiles in					Ci Ci Ci	. 000	1814170 66/67/11	4191 4/10/01
Toxicity Determin	813	ક્ર	09/269,911	2/28/00	2/28/00 Granted	09/269/911	2/28/00 6228589	26569 5/8/01
	802-12	S	09/130,862	86/9/8	8/6/98 Granted	09/130 862	80j8j8	
Method of Detecting the Presence or Absence of a						. 00,000	CAPCCZO DEJOZO	10/27/6
Plurality of Target Sequences Using								
	802-08	US.	09/090,809	6/4/98	Granteri	09/090 909	entria eca entria	
DNA Sequencing by Parallel Oligonucleolide						000,000	CCGN070 DR/HM	10,927/8 CC6.01
.	805-02	S.	09/280,270	3/29/99	Granted	09/280,270	3/29/99 6306.597	10/23/01
Oligonuclectide Tags for Sorting and Identification	802-07	S	09/053.116	4/1/98	Granted	00/053/116		_
1					Cicina	201000	8287C50 06/1/1	3/5/02
	815 US	ß	09/424,028	11/16/99	Cranker —	09/424:028	14/46/00/04/0	
Solid Phase Selection of Differentially Expressed			-	1	0.00	10000	0400040 68 MI II I	20/81/0
	822-02	S.	09/227,694	1/8/99	1/8/99 Granier	09/227 694	1 100 00	
Method of mapping restriction sites in			-		Ci ci coco	1001	Znol I colegioni	50/87/I.
	816-01 US	S	09/446,081	3/27/00	3/27/00 Granted	09/446-091	307/00 EE4	
SYSTEM AND APPARATUS FOR SEQUENTIAL					1	000 4 100 000	9200000000000	00/23 2/ 1/03
	815-01 AU	å	83651/01		Inactive	83651/01		
METHOD OF MAPPING RESTRICTION SITES IN						,		
	816-01 WOJP	5	11505776	6/25/98	6/25/98 Panding	11505778	556	
DATA ANALYSIS AND DISPLAY SYSTEM FOR				1	9	. 1000	96/27/0	
LIGATION-BASED DNA SEQUENCING		S	10/407.089	45563 Dans		107/07/060		
DATA ANALYSIS AND DISPLAY SYSTEM FOR			1000	1000	2	800°104001	4/2/03	
	833-01 AU	2	38391/01	3/45/04 Ellou		2000-201	_	

TRADEMARK REEL: 003004 FRAME: 0744

Page 15

NO.390

P.28

EXHIBIT "C"

TRADEMARKS

TRADEMARK

DESCRIPTION COUNTRY

SERIAL NO.

REG. NO.

STATUS

See Attached.

500477 v2/HN @q65021.DOC -10-

500640 vI/HN @q@_01!,DOC

RADEMARKS

5.2005	12:07PM	SPE	CIAL:	IZED PAT	ENT				NO.	390	P.29
M S/MT	TM/S	MSM		M	Z	MS	MS	M	MI		
Registered	Registered	Registered	Registered	Registered	Registered	Registered	CLOSED-To Dungeon	Registered	Registered	CLOSED-To Dungeon	
Europe Cmty	Japan	SU	US	SO	US	SU	US	SU	US	US	<u>Andress</u>
Megasort	Megasort	Megaclone	Megaclone	Combi-Tag	Combi-Bead	Lynx	Megatype	MPSS	Megasort	Megaclone	
Kuts for carrying out analysis; Services for laboratory and/or clinical analysis; carrying out laboratory & clinical analysis by selection or segregation, flow separation or by flow	Kits for laboratory and/or clinical analysis, sorting, or segregation by flow sorting or flow cytometry particulate supports carrying immobilized biological molecules, such as nucleic acids; DNA analysis	Providing DNA analysis services for others	Reagents for scientific or research use	Oligonucleotide reagents used in scientific research and clinical research procedures for separation, sorting, or labeling polynucleotide analytes	Microbead reagents used in scientific and clinical research procedures for separating, sorting, labeling, or analyzing Combi-Bead polynucleotide analytes	Providing DNA analysis services for others	Providing DNA analysis services for others	DNA sequence analyzer for parallel analysis of multiple nucleic acids attached to separate microparticles disposed in a planar array, and parts thereof	Kits consisting primarily of probes for sorting particulate supports carrying immobilized biological molecules, such as nucleic acids, for scientific or research use	Reagents for scientific or research use; diagnostics reagents for clinical or medical laboratory use	Wall of Mark of Mark of Mark of the Salah of
1 261 791	11-76484	76/163424	76/163492	75/788982	75/910313	76/163491	76/162496	75/368237	75/653709	75/631946	THE CO.
11/28/2001	04/19/2002	2.640.604	2 646 805	2.505.260	2.503.036	2.650.334	There is no Registration No. for this one as it was abandoned	2,756,427	2,607,815 TRAD	There is no Registration No. for this one as it was	A MORESERVA

REEL: 003004 FRAME: 0746

JAN.	5.2005	12:07PM	SPECIALIZED PATENT	NO.390	P.30

500640 v1/HN @q@_611.DOC

		:07PM	SPECIAL:	IZED PATENT				NO.39	0 P.30
	M. M.	M	M	TM	M	M	Z	K	
	Registered	Registered	Registered	Registered	Registered	Registered	Registered	Registered	
	S	Europe Craty	Europe Cmty	Europe	Japan	Japan	Japan	Japan	
(2000)	Lynx Genecatalog and design floox design	Combi-Tag	MPSS	Megaclone	1	Combi-Tag	MPSS	Megacione	8
HALLMALL WALLEADER	Lynx beauty care; veterinary & agricultural services, scientific & Genecatalog industrial research; computer programming, services of a and design inedical bacteriological or chemical laboratorium, technical flox design) advisory services.	n scientific research ating, sorting, and/	Chemicals used in industry and science; chemical reagents for scientific and diagnostic use, reagents for use in medicine; equipment for nucleic acid analysis	Particulate supports with immobilized biological molecules for use in scientific research or clinical procedures, such as nucleic acid probe hybridication, gene expression analysis, DNA sequencing, drug discovery, and kits that include such supports	Oligonucleotide for clinical & medical purposes for separating, sorting and/or labeling polynucleotide analytes	Oligonucleotide for separating, sorting and/or labeling polynucleotide analytes [other than for medical and veterinary purposes]	Equipment for nucleic acid analysis, other physical or chemical apparatus/instruments, measuring apparatus/instruments	Particulate supports with immobilized biological molecules for use in scientific research or clinical procedures, such as nucleic acid probe hybridization, gene expression analysis, DNA sequencing, drug discovery & kits that include such supports	cytometry particulate supports carrying immobilized biological molecules
76/216817		1 520 428	779 363	1 163 609	2001-32345	2000-6598	10-28514	11-42716	多色彩
2,661,846		04/09/2001	09/08/1999	0,007/2000	06/01/2001	1000/2/2011	12/2///2000	TRADEN	IAR

REEL: 003004 FRAME: 0747

12	2:07F	PM	SPE	CIAL	IZED P	ATENT								YO.390	ð 1	∍. <u>31</u>
		MS	MS	SM	MS	MS	X	TM/S	MS	MS	M	MS	MS	TM,		
Proposition of	Registered	Pending	Registered	Registered	Registered	Registered	Registered		Registered	Registered	Registered	Dungeon	Registered	THE STATE OF THE S		
10 G P 141.1		US	US	Cmty	Cmty	Europe	Cmty	Europe	Japan	Japan	Japan	Japan	US			(Calaba)
in fragi	Tyny	MPSS	Megasort	MPSS	Megatype	Megacione	Lynx		MPSS	Megalype	Megaclone	Lynx	design)	s ig	Ġ	
may research or Berries for secondition of Highest father	Reagents for analysis, cloning, sequencing, identification,	Providing DNA analysis services for others	for others	Reagents for scientific or research use; reagents for clinical or medical laboratory use; providing DNA analysis services	Providing DNA analysis services for others	Providing DNA analysis services for others	Providing DNA analysis services for others	Analysis, cloning, sequencing, identification, characterization and research of genes	services.	industrial research; computer programming, services of a medical bacteriological or chemical laboratorium, technical	Lynx Scientific apparatus & instruments; medical, hygienic & Genecatalog beauty care, veterinary & agricultural services, scientific &	CONTRACTOR OF THE PROPERTY OF				
1 7007/7010r	COAC! C3 193	76/259445	76/259442	2 208 387	2 207 421	2 208 767	2 208 148		41358/2001	41357/2001	41356/2001	41355/2001	76/216971			
+0.07.01.14.0	OÀTI E POOA	2,856,295	2,586,627	03/06/2002	06/12/2002	05/17/2002	10/14/2002		07/05/2002	07/05/2002	07/05/2002		2,661,848			

REEL: 003004 FRAME: 0748

500640 v1/HN @q@_011.DOC Exhibit "D" attached to that certain Intellectual Property Security Agreement dated <u>Pletanky Zo</u>, 2004.

EXHIBIT "D"

MASK WORKS

MASK WORK

DESCRIPTION COUNTRY SERIAL NO. REG. NO. **STATUS**

None.

@q6502!.DQC -1 I -

Exhibit "E" attached to that certain Intellectual Property Security Agreement dated <u>Pletinble 20</u>, 2004.

EXHIBIT "E"

LICENSES

- 1. Colony Technology Sharing Agreement, dated as of March 22, 2004, between Solexa Limited and the Company.
- 2. Deed, dated October 25, 2004, between Solexa Limited and the Company.
- 3. Master Development Agreement, dated October 28, 2004, by and between Solexa Limited and the Company.
- 4. Collaboration Agreement, dated October 1, 2000, by and between Takara Shuzo Co., Ltd. and the Company, as amended on December 19, 2002 and June 30, 2003.

(56120/938)

868803.1

500477 v2/HN @q6502!.DOC -12-